# EDGAR Filing Document

**Accession Number:** 0001830974
**File Stem:** 0001213900-26-065638
**Filing Date:** 2026-6
**Character Count:** 137683
**Document Hash:** f29c4a72021f424bdb186b634f135dfa
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-065638.hdr.sgml**: 20260605

**ACCESSION NUMBER**: 0001213900-26-065638

**CONFORMED SUBMISSION TYPE**: N-CSR

**PUBLIC DOCUMENT COUNT**: 8

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260605

**DATE AS OF CHANGE**: 20260605

**EFFECTIVENESS DATE**: 20260605

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aspiriant Capital Appreciation Fund
- **CENTRAL INDEX KEY:** 0001830974

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** N-CSR
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-23619
- **FILM NUMBER:** 261067881

**BUSINESS ADDRESS:**
- **STREET 1:** C/O UMB FUND SERVICES, INC.
- **STREET 2:** 235 WEST GALENA STREET
- **CITY:** MILWAUKEE
- **STATE:** WI
- **ZIP:** 53201
- **BUSINESS PHONE:** 414-299-2200

**MAIL ADDRESS:**
- **STREET 1:** C/O UMB FUND SERVICES, INC.
- **STREET 2:** 235 WEST GALENA STREET
- **CITY:** MILWAUKEE
- **STATE:** WI
- **ZIP:** 53201

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aspiriant Risk-Managed Capital Appreciation Fund
- **DATE OF NAME CHANGE:** 20250723

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ASPIRIANT CAPITAL APPRECIATION FUND
- **DATE OF NAME CHANGE:** 20250718

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ASPIRIANT RISK-MANAGED CAPITAL APPRECIATION FUND
- **DATE OF NAME CHANGE:** 20201103

UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549

**FORM N-CSR**

**CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT**

**INVESTMENT COMPANIES**

Investment Company Act File Number <u>811-23619</u>

**Aspiriant Capital Appreciation Fund** 

(Exact name of registrant as specified in charter)

c/o UMB Fund Services, Inc.

235 West Galena Street

Milwaukee, WI 53212

(Address of principal executive offices) (Zip code)

Ann Maurer

235 West Galena Street

Milwaukee, WI 53212

(Name and address of agent for service)

Registrant's telephone number, including area code: <u>(414) 299-2217</u>

Date of fiscal year end: <u>March 31</u>

Date of reporting period: <u>March 31, 2026</u>

**Item 1. Reports to Stockholders.**

(a) The following is a copy of the report transmitted to shareholders pursuant to Rule 30e-1 under the Investment Company Act of 1940, as amended.

![](taspiriant_logo2.jpg)

#### ASPIRIANT CAPITAL APPRECIATION FUND
**Annual Report**

**March 31, 2026**

------

#### **TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  [Letter to Shareholders (Unaudited)](#T71) | 2 |
|  [Growth of a $25,000 Investment and Fund Performance (Unaudited)](#T72) | 4 |
|  [Consolidated Schedule of Investments](#T73) | 5 |
|  [Consolidated Summary of Investments](#T74) | 7 |
|  [Consolidated Statement of Assets and Liabilities](#T75) | 8 |
|  [Consolidated Statement of Operations](#T76) | 9 |
|  [Consolidated Statements of Changes in Net Assets](#T77) | 10 |
|  [Consolidated Statement of Cash Flows](#T78) | 11 |
|  [Financial Highlights](#T79) | 13 |
|  [Notes to Consolidated Financial Statements](#T80) | 14 |
|  [Report of Independent Registered Public Accounting Firm](#T81) | 26 |
|  [Other Information (Unaudited)](#T82) | 27 |
|  [Fund Management (Unaudited)](#T83) | 30 |

---

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 2 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

#### ASPIRIANT CAPITAL APPRECIATION FUND<br> Letter to Shareholders<br> March 31, 2026 (Unaudited)
The Aspiriant Capital Appreciation Fund ("XACAX" or the "Fund") returned 15.49% for the one-year period ended March 31, 2026. Over the same period, the MSCI ACWI Index ("ACWI" or the "Benchmark") and Russell 2000 Index returned 20.01% and 25.72%, respectively.

The Fund has an allocation to marketable securities through the use of exchange-traded funds and mutual funds, providing the Fund with a level of liquidity and broad exposure to global equities. For the first time in years, global equity securities outpaced US securities. Within the market sleeve, the DFA Global Equity Portfolio out performed the Benchmark, while the GMO Quality Fund underperformed the Benchmark.

Commingled limited partnerships and mutual funds provided exposure to a range of security types (e.g., public equity, public debt, options, futures, forwards, and other derivatives) and strategies (e.g., global macro, equity long/short, relative value, market neutral, arbitrage). Several partnerships underperformed ACWI including those that employed technology focused and long/short strategies. While those with a portion of their investments in publicly traded health care securities outperformed the Benchmark.

Lastly, the Fund's allocations to private equity and venture capital contributed positively to the Fund's performance but underperformed the Benchmark. Venture capital investments as well as health care funds with a private healthcare focus outperformed the Benchmark. Underperformers included our China food focused fund and underlying funds at the very end of their life cycle.

Thank you for your investment in the Fund.

**John Allen<br>*Portfolio Manager<br>Chief Investment Officer, Aspiriant, LLC***

**The performance data quoted represents past performance and is not a guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance information quoted. To obtain performance information current to the most recent month**-end**, please call 1**-877-997-9971**.**

Portfolio composition will change due to ongoing management of the Fund. References to specific securities should not be construed as a recommendation by the Fund, Aspiriant, LLC ("Aspiriant" or the "Adviser") or the distributor.

An investment in the Shares is not suitable for you if you need foreseeable access to the money you invest. The Fund is an appropriate investment only for those investors who can tolerate a high degree of risk and do not require a liquid investment.

The Fund is subject to substantial risks — including market risks, industry concentration risks, strategy risks, valuation risks, and investment advisers to the Investment Funds (the "Underlying Manager") risks. The Fund allocates its assets to Underlying Managers and invests in Investment Funds that invest in actively traded securities and other financial instruments using a variety of strategies and investment techniques that may involve significant risks. Investment Funds generally will not be registered as investment companies under the 1940 Act and, therefore, the Fund will not be entitled to the various protections afforded by the 1940 Act with respect to its investments in Investment Funds. The Adviser will not have any control over the Underlying Managers, thus there can be no assurances that an Underlying Manager will manage its Investment Funds in a manner consistent with the Fund's investment objective.

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 3 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

#### ASPIRIANT CAPITAL APPRECIATION FUND<br>LETTER TO SHAREHOLDERS (Continued)<br> March 31, 2026 (Unaudited)
The Fund intends to offer to repurchase approximately 5% of its outstanding Shares (generally each quarter), and there is no guarantee that Shareholders will be able to sell all of the Shares that they desire to sell in any particular repurchase offer. If a repurchase offer is oversubscribed, the Fund may repurchase only a pro rata portion of the Shares tendered by each Shareholder. The potential for proration may cause some investors to tender more Shares for repurchase than they wish to have repurchased. The decision to offer to repurchase Shares is at the sole discretion of the Board of Trustees (the "Board") and the Board may, under certain circumstances, elect not to offer to repurchase Shares. Various other types of risks are also associated with investments in the Fund, including risks relating to the fund of funds structure of the Fund, risks relating to compensation arrangements and risks relating to industry concentration.

The views expressed are those of the authors at the time created. They do not necessarily reflect the views of other persons in the Aspiriant organization. These views are subject to change at any time based on market and other conditions, and Aspiriant disclaims any responsibility to update such views. No forecasts can be guaranteed. These views may not be relied upon as investment advice or as an indication of trading intent on behalf of any Aspiriant portfolio.

**Please consider the Fund's investment objectives, risks, charges and expenses carefully before investing. The prospectus that contains this and other information about the Fund is available by calling 1**-877-997-9971 **and should be read carefully prior to investing.**

The below referenced, unmanaged indices do not reflect the deduction of fees and taxes associated with a mutual fund, such as investment management and fund accounting fees. Investors cannot invest directly in an index, although they can invest in their underlying securities.

ACWI is a free float-adjusted market capitalization weighted index that is designed to measure the equity performance of developed and emerging markets. ACWI covers the Large and Mid-Capitalization securities as defined by MSCI. Indices are unmanaged and have no fees. The Russell 2000 Index measures the performance of the small-cap segment of the US equity universe. Indices are unmanaged and have no fees. It is not possible to invest directly in an index.

Aspiriant Capital Appreciation Fund is distributed by Distribution Services, LLC. Aspiriant serves as the investment adviser of the Fund. Distribution Services, LLC and Aspiriant are unaffiliated.

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 4 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

#### ASPIRIANT CAPITAL APPRECIATION FUND<br>GROWTH OF A $25,000 INVESTMENT AND FUND PERFORMANCE<br> March 31, 2026 (Unaudited)
![](tlinechart_001.jpg)

The above graph compares a hypothetical $25,000 investment in the Fund's Shares, made at its inception, with similar investment in the MSCI ACWI Index.

---

| | | | |
|:---|:---|:---|:---|
|  **Total Returns as of March 31, 2026** | **1 Year** | **5 Year** | **Annualized <br>Since Inception\*** |
|  Aspiriant Capital Appreciation Fund | 15.49% | 6.77% | 6.77% |
|  MSCI ACWI Index<sup>(1)</sup> | 20.01% | 9.49% | 9.49% |

---

**The performance data quoted represents past performance and is not a guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance information quoted. To obtain performance information current to the most recent month-end, please call 1-877-997-9971, or go to www.aspiriantfunds.com.**

**The Investment Manager has entered into an investment management fee limitation agreement with the Fund, whereby the Investment Manager has agreed to waive its advisory fee from 0.50% to 0.17% through August 1, 2026. This arrangement may be terminated only by the Fund's Board of Trustees.**

<sup>\*</sup>For the period close of business April 1, 2021 (commencement of operations) through March 31, 2026.

<sup>(1)</sup> The MSCI ACWI Index, which captures large and mid-cap representation, is a free float-adjusted market capitalization weighted index that is designed to measure the equity market performance of developed and emerging markets.

Returns include the reinvestment of distributions but do not consider sales charges. Performance is shown for illustrative purposes only and does not predict or depict the performance of the Fund.

The above referenced unmanaged index does not reflect the deduction of fees and taxes associated with a mutual fund, such as investment management and fund accounting fees. Investors cannot invest in an index, although they can invest in their underlying securities.

Returns reflect the reinvestment of distributions made by the Fund, if any. The graph and the performance table above do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or the redemption of Fund shares.

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 5 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

#### ASPIRIANT CAPITAL APPRECIATION FUND<br>CONSOLIDATED SCHEDULE OF INVESTMENTS<br> As of March 31, 2026

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Type of Investment** | **Units / Shares** | **Cost** | **Fair Value** |
|  **MARKETABLE SECURITIES (28.38%)** |  |  |  |  |
|  **EXCHANGE-TRADED FUND (2.96%)** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; iShares MSCI ACWI ETF<sup>a</sup> | Exchange-traded fund | 30849  | $3951142 | $4268576  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **TOTAL EXCHANGE-TRADED FUND** |  |  | **3951142** | **4268576**  |
|  **MUTUAL FUNDS (25.42%)** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; American Funds New Perspective Fund F-3 | Mutual fund | 158134  | 10588408 | 10583876  |
| &nbsp;&nbsp;&nbsp;&nbsp; DFA Global Equity Portfolio - Institutional Class | Mutual fund | 303269  | 10837351 | 11960939  |
| &nbsp;&nbsp;&nbsp;&nbsp; GMO Quality Fund - Class VI<sup>a</sup> | Mutual fund | 432550  | 13419091 | 14079502  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **TOTAL MUTUAL FUNDS** |  |  | **34844850** | **36624317** |
|  **TOTAL MARKETABLE SECURITIES** |  |  | **38795992** | **40892893** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Investment Strategy** | | | **Acquisition <br>Date** |
|  **PORTFOLIO FUNDS<sup>b,c</sup> (72.58%)** |  |  |  |  |
|  **PARTNERSHIP INTERESTS (72.58%)** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Accolade Partners VII-C, L.P.<sup>d</sup> | Private Equity | $1417500 | $1889282 | 12/7/2020 |
| &nbsp;&nbsp;&nbsp;&nbsp; AQR Delphi Long-Short Equity Fund, L.P. | Long/Short | 5500000 | 11375433 | 4/1/2020 |
| &nbsp;&nbsp;&nbsp;&nbsp; Black River Capital Partners Fund (Food) L.P.<sup>a</sup> | Private Equity | 3757759 | 1057565 | 8/5/2011 |
| &nbsp;&nbsp;&nbsp;&nbsp; Blackstone Life Sciences V L.P. | Private Equity | 4689267 | 6462293 | 1/10/2020 |
| &nbsp;&nbsp;&nbsp;&nbsp; Coatue Qualified Partners, L.P. | Long/Short | 3502225 | 9737963 | 11/1/2017 |
| &nbsp;&nbsp;&nbsp;&nbsp; Gavea Investment Fund IV A, L.P. | Private Equity | 1424075 | 232678 | 7/1/2011 |
| &nbsp;&nbsp;&nbsp;&nbsp; H.I.G. Small-Cap & Growth Buyout Fund IV, L.P. | Buyout | 250000 | 250000 | 3/30/2026 |
| &nbsp;&nbsp;&nbsp;&nbsp; Industry Ventures Secondary X, L.P. | Venture Capital | 1320644 | 2154013 | 1/2/2024 |
|  &nbsp;&nbsp;&nbsp;&nbsp;J. Goldman, L.P. | Long/Short | 1000000 | 1038400 | 7/1/2025 |
| &nbsp;&nbsp;&nbsp;&nbsp; KEPE Selling Fund II, L.P.<sup>a</sup> | Private Equity | 90245 | 90423 | 11/15/2024 |
| &nbsp;&nbsp;&nbsp;&nbsp; New Mountain Investments III, L.P.<sup>a</sup> | Buyout | 208517 | 195066 | 12/19/2007 |
| &nbsp;&nbsp;&nbsp;&nbsp; New Mountain Investments VII, L.P. | Buyout | 3543665 | 4119190 | 8/29/2024 |
| &nbsp;&nbsp;&nbsp;&nbsp; Oaktree Opportunities Fund X, L.P. | Private Credit |  | 1096059 | 2/4/2016 |
| &nbsp;&nbsp;&nbsp;&nbsp; Oaktree Opportunities Fund Xb, L.P.<sup>a</sup> | Private Credit | 2424232 | 8430141 | 6/18/2018 |
| &nbsp;&nbsp;&nbsp;&nbsp; RA Capital Healthcare Fund, L.P. | Long/Short | 6000000 | 15827707 | 2/1/2019 |
| &nbsp;&nbsp;&nbsp;&nbsp; RA Capital Nexus Fund III, L.P. | Private Equity | 2000000 | 3427894 | 12/17/2021 |
| &nbsp;&nbsp;&nbsp;&nbsp; Revolution Ventures II, L.P. | Venture Capital | 3516656 | 2605468 | 10/24/2013 |
| &nbsp;&nbsp;&nbsp;&nbsp; Stripes V, L.P. | Private Equity | 9818729 | 14573197 | 7/7/2021 |
| &nbsp;&nbsp;&nbsp;&nbsp; The Children's Investment Fund L.P. | Long/Short | 3000000 | 11243198 | 11/1/2017 |
| &nbsp;&nbsp;&nbsp;&nbsp; Viking Global Opportunities L.P. | Private Equity | 4439210 | 8771199 | 1/1/2021 |
| &nbsp;&nbsp;&nbsp;&nbsp; Vintage V, L.P. | Buyout | 1969564 | 5418 | 8/20/2008 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **TOTAL PARTNERSHIP INTERESTS** |  | **59872288** | **104582587** |  |
|  **TOTAL PORTFOLIO FUNDS** |  | **59872288** | **104582587** |  |

---

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 6 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

#### ASPIRIANT CAPITAL APPRECIATION FUND<br>CONSOLIDATED SCHEDULE OF INVESTMENTS (Continued)<br> As of March 31, 2026

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Type of Investment** | **Units / Shares** | **Cost** | **Fair Value** |
|  **SHORT-TERM INVESTMENT (1.18%)** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Goldman Sachs Financial Square Government Fund, 3.31%<sup>a,e</sup> | Money Market Fund | 1707903 | $1707903 | $1707903 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **TOTAL SHORT-TERM INVESTMENT** |  |  | **1707903** | **1707903** |
|  **TOTAL INVESTMENTS (102.14%)** |  |  | $**100376183** | $**147183383** |
|  Liabilities in excess of other assets (-2.14%) |  |  |  | (3083425) |
|  **TOTAL NET ASSETS (100.00%)** |  |  |  | $**144099958** |

---

<sup>a</sup>All or a portion of this investment is made through the wholly owned subsidiary RMCA Subholding, LLC (see Note 2).

<sup>b</sup>Portfolio Funds are generally offered in private placement transactions and as such are illiquid and generally restricted as to resale (see Notes 3 & 5).

<sup>c</sup>Non-income producing security.

<sup>d</sup>Affiliated investment for which ownership exceeds 5% of the investment's capital (see Note 5).

<sup>e</sup>The rate is the annualized seven-day yield at period end.

All investments are domiciled in the United States of America, except Gavea Investment Fund IV A, L.P., which is domiciled in Brazil.

*See accompanying Notes to Consolidated Financial Statements.*

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 7 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

#### ASPIRIANT CAPITAL APPRECIATION FUND<br>CONSOLIDATED SUMMARY OF INVESTMENTS<br> As of March 31, 2026

---

| | |
|:---|:---|
| **SECURITY TYPE** | **Percent of Total<br>Net Assets** |
|  **MARKETABLE SECURITIES** |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Exchange-Traded Fund | 2.96% |
| &nbsp;&nbsp;&nbsp;&nbsp; Mutual Funds | 25.42 |
|  **TOTAL MARKETABLE SECURITIES** | **28.38** |
|  **PORTFOLIO FUNDS** |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Partnership Interests | 72.58 |
|  **TOTAL PORTFOLIO FUNDS** | **72.58** |
|  **SHORT-TERM INVESTMENT** | **1.18** |
|  **TOTAL INVESTMENTS** | **102.14** |
| &nbsp;&nbsp;&nbsp;&nbsp; Liabilities in excess of other assets | (2.14) |
|  **TOTAL NET ASSETS** | **100.00%** |

---

*See accompanying Notes to Consolidated Financial Statements.*

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 8 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

#### ASPIRIANT CAPITAL APPRECIATION FUND<br>CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES<br> As of March 31, 2026

---

| | |
|:---|:---|
|  **ASSETS:** |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Unaffiliated investments, at fair value (cost $98,958,683) | $145294101 |
| &nbsp;&nbsp;&nbsp;&nbsp; Affiliated investments, at fair value (cost $1,417,500) | 1889282 |
| &nbsp;&nbsp;&nbsp;&nbsp; Cash held in escrow | 3489113 |
| &nbsp;&nbsp;&nbsp;&nbsp; Receivable for investments sold | 120007 |
| &nbsp;&nbsp;&nbsp;&nbsp; Dividend receivable | 32597 |
| &nbsp;&nbsp;&nbsp;&nbsp; Taxes withheld by Portfolio Funds | 46164 |
| &nbsp;&nbsp;&nbsp;&nbsp; Prepaid expenses | 22954 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Assets | $150894218 |
|  **LIABILITIES:** |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Subscriptions received in advance | $3356000 |
| &nbsp;&nbsp;&nbsp;&nbsp; Payable for shares redeemed | 2613693 |
| &nbsp;&nbsp;&nbsp;&nbsp; Deferred tax liability | 512104 |
| &nbsp;&nbsp;&nbsp;&nbsp; Current tax liability | 101662 |
| &nbsp;&nbsp;&nbsp;&nbsp; Management fee payable | 62135 |
| &nbsp;&nbsp;&nbsp;&nbsp; Administration and accounting fees payable | 42562 |
| &nbsp;&nbsp;&nbsp;&nbsp; Administrative services fees payable | 36550 |
| &nbsp;&nbsp;&nbsp;&nbsp; Transfer agent fees and expenses payable | 2056 |
| &nbsp;&nbsp;&nbsp;&nbsp; Custody fees payable | 2004 |
| &nbsp;&nbsp;&nbsp;&nbsp; Other expenses payable | 65494 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Liabilities | 6794260 |
|  **Commitments and contingencies (see Note 3)** |  |
|  **NET ASSETS** | $**144099958** |
|  **NET ASSETS CONSIST OF:** |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Paid-in capital (unlimited shares authorized, par value of $0.001 per share) | 104880477 |
| &nbsp;&nbsp;&nbsp;&nbsp; Total distributable earnings | 39219481 |
|  **NET ASSETS APPLICABLE TO OUTSTANDING SHARES** | $**144099958** |
|  **SHARES ISSUED AND OUTSTANDING** | 12870008  |
|  **NET ASSET VALUE, OFFERING AND REDEMPTION PRICE PER SHARE** | $11.20 |

---

*See accompanying Notes to Consolidated Financial Statements.*

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 9 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

#### ASPIRIANT CAPITAL APPRECIATION FUND<br>CONSOLIDATED STATEMENT OF OPERATIONS<br> For the Year Ended March 31, 2026

---

| | |
|:---|:---|
|  **INVESTMENT INCOME:** |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Dividend income from unaffiliated investments | $652108  |
| &nbsp;&nbsp;&nbsp;&nbsp; Income distributions from unaffiliated Portfolio Funds (net of withholding tax of $2,199) | 306000  |
| &nbsp;&nbsp;&nbsp;&nbsp; Interest income from unaffiliated investments | 501  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Income | 958609  |
|  **EXPENSES:** |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Management fee | 741039 |
| &nbsp;&nbsp;&nbsp;&nbsp; Administration and accounting fees | 166279 |
| &nbsp;&nbsp;&nbsp;&nbsp; Administrative services fees | 148208 |
| &nbsp;&nbsp;&nbsp;&nbsp; Legal fees | 108088 |
| &nbsp;&nbsp;&nbsp;&nbsp; Audit and tax fees | 97543 |
| &nbsp;&nbsp;&nbsp;&nbsp; Excise tax expense | 92441 |
| &nbsp;&nbsp;&nbsp;&nbsp; Trustees' fees and expenses | 63000 |
| &nbsp;&nbsp;&nbsp;&nbsp; Compliance fees | 28062 |
| &nbsp;&nbsp;&nbsp;&nbsp; Registration fees | 27139 |
| &nbsp;&nbsp;&nbsp;&nbsp; Professional fees | 24783 |
| &nbsp;&nbsp;&nbsp;&nbsp; Transfer agent fees and expenses | 24737 |
| &nbsp;&nbsp;&nbsp;&nbsp; Custody fees | 19308 |
| &nbsp;&nbsp;&nbsp;&nbsp; Insurance fees | 4889 |
| &nbsp;&nbsp;&nbsp;&nbsp; Other expenses | 31876 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total expenses | 1577392 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Expenses waived by Investment Manager | (489086) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net expenses | 1088306 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net investment loss before taxes | (129697) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Current tax (expense)/benefit | (3659) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net investment loss, net of income tax | (133356) |
|  **REALIZED AND UNREALIZED GAIN (LOSS):** |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Net realized gain (loss) on unaffiliated investments | 2296141 |
| &nbsp;&nbsp;&nbsp;&nbsp; Current tax (expense)/benefit | 53300 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net realized gain (loss) on investments, net of income tax | 2349441 |
| &nbsp;&nbsp;&nbsp;&nbsp; Capital gain distributions from unaffiliated marketable securities | 2128033 |
| &nbsp;&nbsp;&nbsp;&nbsp; Net change in unrealized appreciation (depreciation) on: |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unaffiliated investments | 16145129 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Affiliated investments | 298883 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deferred tax (expense)/benefit | (286854) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total net change in unrealized appreciation (depreciation), net of deferred income tax | 16157158 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total net realized and unrealized gain (loss), net of income tax | 20634632 |
|  **Net Increase in Net Assets Resulting from Operations** | $**20501276** |

---

*See accompanying Notes to Consolidated Financial Statements.*

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 10 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

#### ASPIRIANT CAPITAL APPRECIATION FUND<br>CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS

---

| | | |
|:---|:---|:---|
|  | **For the <br>Year Ended <br>March 31, <br>2026** | **For the <br>Year Ended <br>March 31, <br>2025** |
|  **CHANGE IN NET ASSETS FROM:** |  |  |
|  **OPERATIONS:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Net investment income (loss), net of income tax | $(133356) | $71057  |
| &nbsp;&nbsp;&nbsp;&nbsp; Net realized gain on investments, net of income tax | 2349441 | 2503192  |
| &nbsp;&nbsp;&nbsp;&nbsp; Capital gain distributions from marketable securities | 2128033  | 1538414 |
| &nbsp;&nbsp;&nbsp;&nbsp; Net change in unrealized appreciation (depreciation) on investments, net of deferred income tax | 16157158  | (361846) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in Net Assets Resulting from Operations | 20501276 | 3750817  |
|  **DISTRIBUTIONS TO SHAREHOLDERS:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Income and capital gain distributions | (11429423) | (16434070) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in Net Assets Resulting from Distributions | (11429423) | (16434070) |
|  **CAPITAL SHARE TRANSACTIONS:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Shares sold | 2763000  | 2565000 |
| &nbsp;&nbsp;&nbsp;&nbsp; Shares issued for reinvestment of distributions | 8367521  | 12292500 |
| &nbsp;&nbsp;&nbsp;&nbsp; Shares redeemed | (12638625) | (15831324) |
| &nbsp;&nbsp;&nbsp;&nbsp; Change in Net Assets Resulting from Capital Transactions | (1508104) | (973824) |
| &nbsp;&nbsp;&nbsp;&nbsp; Change in Net Assets | $7563749  | $(13657077) |
|  **NET ASSETS:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Beginning of period | 136536209  | 150193286 |
| &nbsp;&nbsp;&nbsp;&nbsp; End of period | $144099958 | $136536209 |
|  **TRANSACTIONS IN SHARES:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Shares sold | 240053  | 230389 |
| &nbsp;&nbsp;&nbsp;&nbsp; Shares issued for reinvestment of distributions | 761376  | 1162961 |
| &nbsp;&nbsp;&nbsp;&nbsp; Shares redeemed | (1117080) | (1438494) |
| &nbsp;&nbsp;&nbsp;&nbsp; Change in Shares Outstanding | (115651) | (45144) |

---

*See accompanying Notes to Consolidated Financial Statements.*

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 11 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

#### ASPIRIANT CAPITAL APPRECIATION FUND<br>CONSOLIDATED STATEMENT OF CASH FLOWS<br> For the Year Ended March 31, 2026

---

| | |
|:---|:---|
|  **CASH FLOWS FROM OPERATING ACTIVITIES:** |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Net increase in net assets from operations | $20501276  |
| &nbsp;&nbsp;&nbsp;&nbsp; Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by operating activities: |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Purchases of long-term investments | (15594567) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proceeds from sales of long-term investments | 28360897 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Realized gain on the disposition of Portfolio Funds | 1568735 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Return of capital distribution proceeds | 4144395  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Purchases of short-term investments, net | (33190) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net realized (gain) loss on investments | (2296141) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Capital gain distributions from unaffiliated marketable securities | (2128033) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net change in unrealized (appreciation) depreciation on investments | (16444012) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in operating assets and liabilities: |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Receivable for investments sold | 134499  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dividend receivable | 11913  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taxes withheld by Portfolio Funds | (8329) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepaid expenses | (6787) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administration and accounting fees payable | 1380  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Management fee payable | 779 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administrative services fees payable | 459 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deferred tax liability | 286854  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Current tax liability | (519641) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Transfer agent fees and expenses payable | (38) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Custody fees payable | (3073) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other expenses payable | (38202) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Net Cash Provided by Operating Activities** | 17939174  |
|  **CASH FLOWS FROM FINANCING ACTIVITIES:** |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Shares sold (net of subscriptions received in advance) | 6119000  |
| &nbsp;&nbsp;&nbsp;&nbsp; Distributions (net of reinvestment of distributions) | (3061902) |
| &nbsp;&nbsp;&nbsp;&nbsp; Shares redeemed (net of payable for shares redeemed) | (17608041) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Net Cash Used in Financing Activities** | (14550943) |
|  **Net Change in Cash and Cash held in escrow** | 3388231  |
| &nbsp;&nbsp;&nbsp;&nbsp; **Cash and Cash held in escrow at Beginning of Year**<sup>1</sup> | 100882  |
| &nbsp;&nbsp;&nbsp;&nbsp; **Cash and Cash held in escrow at End of Year**<sup>1</sup> | $3489113  |

---

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 12 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

#### ASPIRIANT CAPITAL APPRECIATION FUND<br>CONSOLIDATED STATEMENT OF CASH FLOWS (Continued)<br> For the Year Ended March 31, 2026

---

| | |
|:---|:---|
|  **Supplemental schedule of non-cash activity:** |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Reinvestment of distributions | $8367521  |
|  **Supplemental cash flow information:** |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Federal income taxes paid, net of refunds | $562441 |
| &nbsp;&nbsp;&nbsp;&nbsp; State income taxes paid, net of refunds<sup>2</sup> | $10528 |

---

 <sup>1</sup> Cash includes cash and cash held in escrow, as outlined further on the Consolidated Statement of Assets and Liabilities.

 <sup>2</sup> Less than 5% of total income tax paid was paid to any single state.

*See accompanying Notes to Consolidated Financial Statements.*

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 13 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

#### ASPIRIANT CAPITAL APPRECIATION FUND<br>FINANCIAL HIGHLIGHTS<br> Per share data and ratios for a share outstanding throughout each period.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **For the <br>Year Ended <br>March 31, <br>2026\*** | **For the <br>Year Ended <br>March 31, <br>2025\*** | **For the <br>Year Ended <br>March 31, <br>2024\*** | **For the <br>Year Ended <br>March 31, <br>2023** | **For the <br>Year Ended <br>March 31, <br>2022<sup>1</sup>** |
|  Net Asset Value, Beginning of Period | $10.51 | $11.53 | $10.32 | $10.93 | $10.00 |
|  Income from Investment Operations |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Net investment income (loss)<sup>2</sup> | (0.01) | 0.01 | 0.04 | (0.03) | (0.03) |
| &nbsp;&nbsp;&nbsp;&nbsp; Net realized and unrealized gain (loss) on investments | 1.62 | 0.27 | 1.36 | (0.58) | 0.96 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total from investment operations | 1.61 | 0.28 | 1.40 | (0.61) | 0.93 |
|  Less Distributions: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; From net investment income |  | (0.37) |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; From net realized gain | (0.92) | (0.93) | (0.19) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total distributions | (0.92) | (1.30) | (0.19) |  |  |
|  Net Asset Value, End of Period | $11.20 | $10.51 | $11.53 | $10.32 | $10.93 |
|  Total Return | 15.49% | 2.37% | 13.73% | (5.58)% | 9.30% |
|  **RATIOS AND SUPPLEMENTAL DATA** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Net assets, end of period (in thousands) | $144100 | $136536 | $150193 | $125995 | $148385 |
| &nbsp;&nbsp;&nbsp;&nbsp; Net investment income (loss)<sup>3</sup> | (0.09)%<sup>4</sup> | 0.05%<sup>4</sup> | 0.34% | (0.30)% | (0.25)% |
| &nbsp;&nbsp;&nbsp;&nbsp; Expenses before expense waiver and tax expense/(benefit)<sup>3,5</sup> | 1.06% | 1.00% | 1.00% | 1.05% | 0.95% |
| &nbsp;&nbsp;&nbsp;&nbsp; Expense waiver | (0.33)% | (0.35)% | (0.40)% | (0.40)% | (0.40)% |
| &nbsp;&nbsp;&nbsp;&nbsp; Expenses net of expense waiver but before tax expense/(benefit)<sup>3,6</sup> | 0.73% | 0.65% | 0.60% | 0.65% | 0.55% |
| &nbsp;&nbsp;&nbsp;&nbsp; Income taxes/(benefit)<sup>7</sup> | 0.16% | 0.29% | 0.29% | 0.00% | 0.00% |
| &nbsp;&nbsp;&nbsp;&nbsp; Expenses net of expense waiver and after tax expense/(benefit)<sup>3,8</sup> | 0.89% | 0.94% | 0.89% | 0.65% | 0.55% |
| &nbsp;&nbsp;&nbsp;&nbsp; Portfolio turnover rate | 11% | 75% | 82% | 6% | 13% |

---

 <sup>\*</sup> Includes consolidated accounts of RMCA Subholding, LLC (See Note 2).

 <sup>1</sup> Reflects operations from April 1, 2021 (commencement of operations) to March 31, 2022.

 <sup>2</sup> Per share data is computed using the average shares method.

 <sup>3</sup> The ratios of expenses and net investment income or loss to average net assets do not reflect the Fund's proportionate share of income and expenses of underlying investment companies in which the Fund invests.

 <sup>4</sup> Includes income tax expense/(benefit) of 0.39% and 0% derived from income for the year ended March 31, 2025 and March 31, 2026, respectively.

 <sup>5</sup> Represents the ratio of expenses to average net assets excluding the expense waiver by the Investment Manager and current and deferred tax expense/(benefit) (see Notes 6 and 8).

 <sup>6</sup> Represents the ratio of expenses to average net assets including the expense waiver by the Investment Manager and excluding current and deferred tax expense/(benefit) (see Notes 6 and 8).

 <sup>7</sup> Includes deferred tax expense/(benefit) derived from the net investment income/loss and realized and unrealized gains/losses (see Note 8).

 <sup>8</sup> Represents the ratio of expenses to average net assets including the expense waiver by the Investment Manager and current and deferred tax expense/(benefit) (see Notes 6 and 8).

*See accompanying Notes to Consolidated Financial Statements.*

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 14 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

#### ASPIRIANT CAPITAL APPRECIATION FUND<br> Notes to Consolidated Financial Statements<br> March 31, 2026
1. ORGANIZATION

Aspiriant Capital Appreciation Fund (f/k/a Aspiriant Risk-Managed Capital Appreciation Fund) (the "Fund") is a Delaware statutory trust registered under the Investment Company Act of 1940, as amended (the "1940 Act"), as a non-diversified, closed-end management investment company. The Fund operates under an Agreement and Declaration of Trust dated November 10, 2020. The Fund commenced its operations on April 1, 2021, after the conversion of the Global Capital Opportunities, L.P. (the "Private Fund"), a privately offered investment fund managed by the Investment Manager (as defined below) with investment policies, objectives, guidelines, and restrictions that were in all material respects equivalent to those of the Fund. The Fund offers shares of beneficial interest ("Shares"). Aspiriant, LLC serves as the investment adviser (the "Investment Manager") of the Fund. The Investment Manager is an investment adviser registered with the Securities and Exchange Commission (the "SEC") under the Investment Advisers Act of 1940, as amended. The investment objective of the Fund is to seek long-term capital appreciation. The Fund is a "fund of funds" that intends to invest primarily in general or limited partnerships, U.S. and foreign funds, corporations, trusts or other investment vehicles (collectively, "Investment Funds") that invest or trade in a wide range of securities. The Fund intends to invest its assets in U.S. and foreign markets, including emerging markets, securities and Investment Funds.

The Board of Trustees (the "Board") of the Fund has the overall responsibility for monitoring the operations of the Fund, including the Investment Manager.

2. SIGNIFICANT ACCOUNTING POLICIES

**Basis of Preparation and Use of Estimates –** The Fund is an investment company and follows the accounting and reporting guidance under Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 946, Financial Services – Investment Companies ("ASC 946"). The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP"). The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as reported amounts of increases and decreases in net assets from operations during the reporting period. Actual results could differ from these estimates.

**Segment Reporting –** The Fund operates as a single operating segment. The Fund's long-term strategic asset allocation is predetermined in accordance with the terms of its prospectus, based on a defined investment strategy which is executed by the Fund's portfolio managers as a team. The Fund's income, expenses, assets, and performance are regularly monitored and assessed as a whole by certain officers of the Fund, acting as the Chief Operating Decision Maker (the "CODM"). The CODM is responsible for the oversight functions of the Fund, using the information presented in the financial statements and financial highlights.

**Consolidation of a Subsidiary –** RMCA Subholding, LLC (the "Subsidiary), is a wholly-owned corporate subsidiary of the Fund. The Consolidated Schedule of Investments, Consolidated Statement of Assets and Liabilities, Consolidated Statement of Operations, Consolidated Statements of Changes in Net Assets, Consolidated Statement of Cash Flows and the Consolidated Financial Highlights of the Fund include the accounts of its Subsidiary. As of and for the year ended March 31, 2026, all intercompany accounts and transactions have been eliminated in consolidation. The inception date of the Subsidiary was January 1, 2024. On March 31, 2026, the Subsidiary had net assets of $15,729,672 which equals 10.9% of the Fund's net assets.

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 15 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

#### ASPIRIANT CAPITAL APPRECIATION FUND<br> Notes to Consolidated Financial Statements (Continued) <br> March 31, 2026
2. SIGNIFICANT ACCOUNTING POLICIES (Continued)

**Cash –** Cash and cash held in escrow for Shares tendered and Shares received in advance, if any, may include demand deposits. Such deposits, at times, may exceed federally insured limits. The Fund has not experienced any losses in such accounts and does not believe it is exposed to any significant credit risk on such accounts.

**Investment Valuation –** The Board has delegated day-to-day management of the valuation process to the Investment Manager as the appointed Valuation Designee, which has established a valuation committee to carry out this function. The Valuation Designee is subject to the oversight of the Board. The Valuation Designee is responsible for assessing and managing key valuation risks, and is generally to review valuation methodologies, valuation determinations, and any information provided by the Investment Manager.

**Investments in Portfolio Funds –** As a practical expedient, the Fund estimates the fair value of interests in Portfolio Funds ("Portfolio Funds' Interests") that do not have a readily determinable fair value using the net asset value ("NAV") per share (or equivalent, such as member units, or an ownership interest in partners' capital to which a proportionate share of net assets is attributed) of the Portfolio Funds as determined by the respective investment manager ("Portfolio Fund's Manager"), if the NAV per share of the Portfolio Fund (or its equivalent) is calculated in a manner consistent with measurement principles in ASC 946 as of the reporting entity's measurement date. If the NAV per share (or its equivalent) of the Portfolio Fund is not as of the Fund's measurement date or is not calculated in a manner consistent with the measurement principles of ASC 946, the Fund may adjust the most recent NAV per share (or its equivalent) as necessary in order to estimate the fair value for the Portfolio Fund in a manner consistent with the measurement principles of ASC 946 as of the Fund's measurement date. The Fund will deviate from the NAV (or its equivalent) if it is probable at the measurement date that the Fund will redeem a portion of a Portfolio Fund at an amount different from the NAV per share (or its equivalent).

Investments in Portfolio Funds are subject to the terms of the Portfolio Funds' offering documents. Valuations of Portfolio Funds may be subject to estimates and are net of management and performance incentive fees or allocations payable to the Portfolio Funds' Managers as required by the Portfolio Funds' offering documents. If the Valuation Designee determines that the most recent NAV (or its equivalent) reported by the Portfolio Fund does not represent fair value or if the Portfolio Fund fails to report a NAV to the Fund, a fair value determination is made under procedures established by and under the general supervision of the Valuation Designee. Because of the inherent uncertainty in valuation, the estimated values may differ from the values that would have been used had a ready market for the securities existed, and the differences could be material. Prospective investors should be aware that situations involving uncertainties as to the value of portfolio positions could have an adverse effect on the Fund's net assets if the judgments of the Valuation Designee, or the Portfolio Funds' Managers should prove to be incorrect. The Portfolio Funds' Managers only provide determinations of the NAV of each Portfolio Fund on a monthly/quarterly basis, in which event it will not be possible to determine the NAV of the Fund more frequently. The Portfolio Funds' Interests in which the Fund invests or plans to invest are generally illiquid. The Fund may not be able to dispose of Portfolio Funds' Interests that it has purchased. As of March 31, 2026, investments in Portfolio Funds were valued at $104,582,587, which represented 72.58% of the NAV of the Fund.

**Investments in Marketable Securities –** Investments in marketable securities listed or traded on an exchange are valued at their last traded price, as of the exchange's official close of business. The Fund does not adjust the quoted price for these investments even in situations where the Fund holds a large position and a sale could reasonably impact the quoted price.

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 16 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

2. SIGNIFICANT ACCOUNTING POLICIES (Continued)

Redeemable securities issued by open-end investment companies and open-end foreign funds are valued at the respective investment company's or foreign fund's applicable NAV per share, with the exception of exchange-traded open-end investment companies which are priced as marketable securities.

**Investment Transactions and Related Investment Income –** All investment transactions are recorded on the trade date. Interest income on cash held in the Fund's interest-bearing accounts is recognized on an accrual basis. Dividend income is recorded on ex-dividend dates. Distributions from marketable securities are classified as investment income or realized gains based on the U.S. income tax characteristics of the distribution. Distributions received from Portfolio Funds are recorded on the effective date, based on the character determined by the Portfolio Fund. Return of capital or security distributions received from Portfolio Funds and securities are accounted for as a reduction to cost. Net realized gain or loss on investments includes net investment gains or losses from marketable securities and realized gains or losses indirectly allocated to the Fund from investments in Portfolio Funds. Realized gains and losses from investments in Portfolio Funds are recognized when reported by those Portfolio Funds. Realized gains and losses from other investments are recorded on a specific identification basis.

**Foreign Currency Translation –** The books and records of the Fund are maintained in U.S. dollars. Assets and liabilities denominated in foreign currencies are translated into U.S. dollar equivalents using period-end spot foreign currency exchange rates. Purchases and sales of investments, and their related income and expenses are translated at the rate of exchange on the respective dates of such transactions. Realized and unrealized gains and losses resulting from foreign currency changes are reflected in the Consolidated Statement of Operations as a component of net realized gain/(loss) and net change in unrealized appreciation on marketable securities and Portfolio Funds.

**Federal Income Taxes –** See Note 8 — Federal Tax Information for more detailed federal tax information.

It is the Fund's intention to comply with the special provisions of Subchapter M of the Internal Revenue Code applicable to regulated investment companies ("RIC"). As provided therein, in any tax year in which a Fund generates 90% of its gross income from qualifying sources under Section 851(b)(2) of the Internal Revenue Code, a Fund's portfolio holds at least 50% of its assets in qualifying assets at the end of each quarter, and distributes at least 90% of its taxable income, such Fund (but not the shareholders) will be relieved of federal income tax on the income distributed. If, in any tax year, the Fund does not meet the requirements to qualify as a RIC, the Fund will be treated as a taxable corporation for federal income tax purposes and as such will be obligated to pay federal, state and local income tax on taxable income.

The Subsidiary is a wholly owned taxable domestic corporation for tax reporting and has a tax year end of September 30. The Subsidiary is subject to federal, state and local income taxes.

FASB ASC Topic 740, Income Taxes ("ASC 740") requires an evaluation of tax positions taken (or expected to be taken) in the course of preparing the Fund's tax return to determine whether these positions meet a "more likely than not" standard that, based on the technical merits, have a more than fifty percent likelihood of being sustained upon examination by a taxing authority. A tax position that meets the "more likely than not" recognition threshold is measured to determine the amount of benefit to recognize in the financial statements. The Fund recognizes interest and penalties, if any, related to unrecognized tax benefits as income tax expense in the Consolidated Statement of Operations.

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 17 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

2. SIGNIFICANT ACCOUNTING POLICIES (Continued)

ASC 740 requires management of the Fund to analyze all open tax years for all major jurisdictions that may be subject to examination by a tax authority. The open tax years can include current year plus the prior three tax years, or all years if the Fund has been in existence for less than three years. As of and during the year ended March 31, 2026, the Fund has not recorded a liability for any unrecognized tax benefits. The Fund has no examinations in progress and is not aware of any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly change in the next twelve months.

3. FAIR VALUE DISCLOSURE

In accordance with FASB ASC 820-10, Fair Value Measurement ("ASC 820"), the Fund discloses the fair value of its investments in a hierarchy that prioritizes the inputs to valuation techniques used to measure the fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level I measurement) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level III measurements). ASC 820 provides three levels of the fair value hierarchy as follows:

*Level I* — Unadjusted quoted prices for identical assets or liabilities in active markets that are accessible at the measurement date and on an-ongoing basis. Investments in marketable securities are classified at Level I in the fair value hierarchy.

*Level II* — Valuations based on observable inputs other than quoted prices in active markets for identical assets or liabilities.

*Level III* — Valuation techniques that require inputs that are both significant to the fair value measurement and are unobservable (e.g. supported by little or no market activity).

The following table summarizes the valuation of the Fund's investments as of March 31, 2026, by the fair value hierarchy levels:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Fair Value Measurements** | **Fair Value Measurements** | **Fair Value Measurements** | **Fair Value Measurements** | **Fair Value Measurements** |
| **Investments** | **Level I** | **Level II** | **Level III** | **NAV as Practical<br>Expedient** | **Total** |
|  Marketable Securities  | $40892893 | $— | $— | $— | $40892893 |
|  Portfolio Funds  |  |  |  | 104582587 | 104582587 |
|  Short-term Investment  | 1707903 |  |  |  | 1707903 |
|  **Total Investments**  | $**42600796** | $**—** | $**—** | $**104582587** | $**147183383** |

---

Investments in Portfolio Funds valued at the NAV as practical expedient are not required under U.S. GAAP to be classified in the fair value hierarchy, however, they are included in the table above to reconcile the total value of investments.

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 18 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

3. FAIR VALUE DISCLOSURE (Continued)

A listing of the Portfolio Fund types held by the Fund and the related attributes, as of March 31, 2026 are shown in the table below:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Investment Category** | **Fair Value<br>(in 000's)** | **Unfunded<br>Commitments<br>(in 000's)** | **Remaining<br>Life\*** | **Redemption<br>Frequency\*** | **Notice Period<br>(in days)** | **Redemption<br>Restriction<br>Terms\*** |
|  Core <sup>(1)</sup>  | $57994 | $— | Indefinite | Monthly - <br>Bi-yearly | 30-120 | May be subject to lockup periods (of up to<br>2 years) and/or investor and/or fund level gates of up to 25% per withdrawal date |
|  Opportunistic <sup>(2)</sup> | 46589 | 35245 | Up to 11 years |  | N/A | N/A |
|  | $**104583** | $**35245**<sup>(3)</sup> |  |  |  |  |

---

<sup>(1)</sup> Investments in commingled limited partnerships that have exposure to a range of security types.

<sup>(2)</sup> Consists of both private equity and venture capital investments.

<sup>(3)</sup> As of March 31, 2026, the Fund had total outstanding commitments of $35,244,800 to the partnership interests of Portfolio Funds.

\* The information summarized in the table above represents the general terms for the specified asset class. Individual Portfolio Funds may have terms that are more or less restrictive than those terms indicated for the asset class as a whole. In addition, most Portfolio Funds have the flexibility, as provided for in their constituent documents, to modify and waive such terms.

4. RISK FACTORS

The Fund's investment activities expose it to various risks, which are associated with the markets and the financial instruments in which it invests (as discussed in Notes 2 and 3). The following summary is not intended to be a comprehensive summary of all risks inherent in investing in the Fund.

**Credit –** Financial instruments which potentially subject the Fund to concentrations of credit risk consist primarily of cash and cash equivalents, including cash held in escrow. Substantially, all of the Fund's cash is deposited with one financial institution. Deposits, at times, may be in excess of federally insured limits. The Fund has not experienced any losses on its cash and cash equivalents, nor does it believe it is exposed to any significant credit risk.

**Liquidity Constraints of Portfolio Funds –** Since the Fund may make additional investments in or effect withdrawals from a Portfolio Fund only at certain times pursuant to limitations set forth in the governing documents of the Portfolio Fund, the Fund from time to time may have to invest a greater portion of its assets temporarily in money market securities than it otherwise might wish to invest and may have to borrow money to repurchase Shares. The redemption or withdrawal provisions regarding the Portfolio Funds vary from fund to fund. Therefore, the Fund may not be able to withdraw its investment in a Portfolio Fund promptly after it has made a decision to do so. Some Investment Funds may impose early redemption fees while others may not. This may adversely affect the Fund's investment return or increase the Fund's expenses and limit the Fund's ability to make offers to repurchase

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 19 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

4. RISK FACTORS (Continued)

Shares from shareholders. Portfolio Funds may be permitted to redeem their interests in-kind. Thus, upon the Fund's withdrawal of all or a portion of its interest in an Investment Fund, it may receive securities that are illiquid or difficult to value.

**Limited Liquidity –** Shares in the Fund provide limited liquidity since shareholders will not be able to redeem Shares on a daily basis. A shareholder may not be able to tender its Shares in the Fund promptly after it has made a decision to do so. There is no assurance that a shareholder will be able to tender its Shares when or in the amount that a shareholder desires. In addition, with very limited exceptions, Shares are not transferable, and liquidity will be provided only through repurchase offers made quarterly by the Fund. Shares in the Fund are therefore suitable only for investors who can bear the risks associated with the limited liquidity of Shares and should be viewed as a long-term investment.

**Non**-Diversified **Status –** The Fund is a "non-diversified" management investment company. Thus, there are no percentage limitations imposed by the 1940 Act on the Fund's assets that may be invested, directly or indirectly, in the securities of any one issuer. Consequently, if one or more securities are allocated a relatively large percentage of the Fund's assets, losses suffered by such securities could result in a higher reduction in the Fund's capital than if such capital had been more proportionately allocated among a larger number of securities. The Fund may also be more susceptible to any single economic or regulatory occurrence than a diversified investment company.

**Leverage Risk –** The Fund does not generally intend to utilize leverage, however, the Fund is permitted to and may, in the sole discretion of the Investment Manager, leverage its investment positions, when deemed appropriate by the Investment Manager for any reason. Furthermore, the strategies implemented by the Portfolio Funds typically are leveraged. While leverage presents opportunities for increasing the total return on investments, it has the effect of potentially increasing losses as well. Accordingly, any event which adversely affects the value of an investment could be magnified to the extent leverage is utilized. The cumulative effect of the use of leverage with respect to any investments in a market that moves adversely to such investments could result in a substantial loss that would be greater than if the investment were not leveraged.

**Market Risk –** Market risk arises primarily from changes in the market value of financial instruments. Exposure to market risk is influenced by a number of factors, including the relationships between financial instruments, and the volatility and liquidity in the markets in which the financial instruments are traded. Local, regional, or global events such as war, acts of terrorism, the spread of infectious illness or other public health issues, recessions, or other events could have a significant impact on the market generally, the value of Funds' investments, and overall performance of the Fund. In many cases, the use of financial instruments serves to modify or offset market risk associated with other transactions, and accordingly, serves to decrease the Fund's overall exposure to market risk. The Fund attempts to control its exposure to market risk through various analytical monitoring techniques.

5. INVESTMENTS BY THE FUND

The Fund, generally, has the ability to liquidate its investments periodically, depending on the type of investment, and for the Portfolio Funds, depending on the provisions of the respective Portfolio Fund's governing agreements. Contribution requirements may also vary based on each Portfolio Fund's governing agreements. Investment advisors who operate Portfolio Funds in which the Fund invests, receive fees for their services. The fees include management fees, performance allocations and direct expenses based upon the NAV of the Fund's investment. These fees are deducted directly from the trading account or Portfolio Fund investment balance in accordance with an advisory or limited partnership agreement. The management fees ranged from 0%–2% (with possible performance or high water mark fees ranging from 0% to 20%).

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 20 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

5. INVESTMENTS BY THE FUND (Continued)

The Fund can liquidate or redeem the marketable securities, open-end investment companies and open-end foreign funds on a daily basis, and there are no restrictions or limitations placed on such investments. Additionally, the terms of the Portfolio Funds' governing documents generally provide for restrictions on transferability, minimum holding periods or lock-ups, the suspension of redemptions/withdrawals or the institution of gates on redemptions/withdrawals, at the discretion of the Portfolio Funds' Managers, and as a result, the Fund may not be able to redeem/withdraw from an investment in a Portfolio Fund without continued exposure to changes in valuations, which could be material.

The Fund's share of Portfolio Funds that were 5% or more of its net assets as of March 31, 2026 is as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Investment<br>(Description of Strategy)** | **Percentage of<br>NAV** | **Fair Value** | **Redemptions Permitted/Restrictions** |
|  RA Capital Healthcare Fund, L.P. (Long/Short Equity)<sup>(a)</sup> | 11.0% | $15827707 | Quarterly liquidity (90 calendar day notice required) after 1 year soft lock-up |
|  Stripes V, LP (Private Equity)<sup>(b)</sup> | 10.1% | $14573197 | 10 year term starting January 2021 subject to 3 1-year extensions upon discretion of GP with the consent of the LP Advisory Committee; redemptions are generally not permitted, but the general partner makes distributions from the sales of the underlying assets |
|  AQR Delphi Long-Short Equity Fund, L.P. (Long/Short Equity)<sup>(a)</sup> | 7.9% | $11375433 | Monthly liquidity (30 calendar day notice required) |
|  The Children's Investment Fund L.P. (Long/Short Equity)<sup>(a)</sup> | 7.8% | $11243198 | Bi-yearly liquidity (4 months' notice required); rebalancing entitlement permitted |
|  Coatue Qualified Partners, L.P. (Long/Short Equity)<sup>(a)</sup> | 6.8% | $9737963 | Annual liquidity (90 calendar day notice required) after 12 month lock-up |
|  Viking Global Opportunities L.P. (Private Equity)<sup>(b)</sup> | 6.1% | $8771199 | After initial 3 year lock-up, rolling 2 year liquidity for liquid capital account and rolling annual liquidity for illiquid capital account (3 calendar month notice required) |
|  Oaktree Opportunities Fund Xb, L.P. (Private Credit)<sup>(c)</sup> | 5.9% | $8430141 | 10 year term starting January 2020 subject to automatic extensions up to 15th anniversary upon discretion of GP and further extension with limited partner approval; redemptions are generally not permitted, but the general partner makes distributions from the sales of the underlying assets |

---

<sup>(a)</sup> This strategy includes funds that employ long and short trading in global equities and attempt to achieve capital appreciation.

<sup>(b)</sup> This strategy includes funds that focus on investment opportunities in private companies with attractive growth prospects and seek to achieve attractive, risk-adjusted absolute returns.

<sup>(c)</sup> This strategy includes funds that focus on investment opportunities in private debt issued by companies that have little or no access to traditional sources of financing and seek to achieve attractive, risk-adjusted absolute returns.

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 21 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

5. INVESTMENTS BY THE FUND (Continued)

As of March 31, 2026, certain of the Fund's investments were deemed to be investments in affiliated issuers under the 1940 Act, primarily because the Fund owns 5% or more of the investment's total capital. The activity resulting from investments in these investments, including dividend income as well as realized gains and losses, is identified in the Consolidated Statement of Operations as transactions with affiliated investments. A listing of these affiliated investments (including activity during the year ended March 31, 2026) is shown below:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Investment <sup>(1)</sup>** | **Fair Value<br>3/31/2025** | **Purchases** | **Proceeds<br>From Sales<br>or Other<br>Dispositions** | **Net Realized<br>Gain (Loss)** | **Net Change<br>in Unrealized<br>Appreciation** | **Fair Value<br>3/31/2026** | **Dividend<br>Income** |
|  Accolade Partners VII-C, L.P.  | $1545399 | $45000 | $— | $— | $298883 | $1889282 | $— |
|  **Total Affiliated Investments**  | $**1545399** | $**45000** | $**—** | $**—** | $**298883** | $**1889282** | $**—** |

---

<sup>(1)</sup> Investment does not issue units or shares.

**6. INVESTMENT MANAGEMENT FEE AND OTHER TRANSACTIONS WITH SERVICE PROVIDERS**

**Investment Management Fee –** The Fund pays to the Investment Manager an investment management fee (the "Investment Management Fee") in consideration of the advisory and other services provided by the Investment Manager to the Fund. Pursuant to an investment management agreement (the "Investment Management Agreement"), the Fund pays the Investment Manager a quarterly Investment Management Fee equal to 0.50% on an annualized basis of the Fund's NAV as of each quarter-end. NAV means the total value of all assets of the Fund, less an amount equal to all accrued debts, liabilities and obligations of the Fund. For purposes of determining the Investment Management Fee payable to the Investment Manager for any quarter, NAV will be calculated prior to any reduction for any fees and expenses of the Fund for that quarter, including, without limitation, the Investment Management Fee payable to the Investment Manager for that quarter, and before giving effect to any repurchase of Shares in the Fund effective as of that date. For the year ended March 31, 2026, the Fund incurred $741,039 in management fees.

The Investment Manager has entered into an investment management fee limitation agreement (the "Management Fee Limitation Agreement") with the Fund, whereby the Investment Manager has agreed to waive 0.33% of its Investment Management Fee. The Management Fee Limitation Agreement automatically renews for consecutive one-year terms (each, a "Current Term"). Neither the Fund nor the Investment Manager may terminate the Management Fee Limitation Agreement during the Current Term. The Investment Management Fee waiver is not subject for recoupment. For the year ended March 31, 2026, the Fund waived $489,086 in Investment Management Fees.

Certain officers of the Fund are employees of the Investment Manager and are not paid by the Fund for the services they provide to the Fund.

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 22 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

6. INVESTMENT MANAGEMENT FEE AND OTHER TRANSACTIONS WITH SERVICE PROVIDERS (Continued)

**Administrative Services Fee –** Pursuant to an administrative services agreement with the Fund, the Investment Manager is entitled to a fee calculated at an annual rate of 0.10%, payable quarterly in arrears, based upon the Fund's net assets as of quarter-end for providing administrative services to the Fund. Such services include the review of shareholder reports and other filings with the SEC; oversight of the Fund's primary service providers; periodic due diligence reviews of the Fund's primary service providers; coordination and negotiation of all of the contracts and pricing relating to the Fund's primary service providers, with the advice of Fund counsel; providing information to the Board relating to the review and selection of the Fund's primary service providers; and all such other duties or services necessary for the appropriate administration of the Fund that are incidental to the foregoing services. For the year ended March 31, 2026, the Fund incurred $148,208 in administrative services fees.

**Distributor –** Distribution Services, LLC is the distributor (also known as principal underwriter) of the Shares of the Fund and acts as the agent of the Trust in connection with the continuous offering of Shares of the Fund.

**Administrator –** UMB Fund Services, Inc. (the "Administrator") serves as administrator to the Fund and provides certain administrative, tax, clerical, bookkeeping and investor related services. For these services the Administrator receives a quarterly fee, as well as reasonable out of pocket expenses. For the year ended March 31, 2026, the Fund incurred $166,279 in administration and accounting fees.

Certain trustees and officers of the Fund are employees of the Administrator and are not paid by the Fund for the services they provide to the Fund.

**Custodian –** UMB Bank, n.a. (the "UMB Bank"), an affiliate of the Administrator, serves as the primary custodian of the assets of the Fund, and may maintain custody of such assets with U.S. and non-U.S. sub custodians (which may be banks and trust companies), securities depositories and clearing agencies in accordance with the requirements of Section 17(f) of the 1940 Act and the rules thereunder. Assets of the Fund are not held by the Investment Manager or commingled with the assets of other accounts other than to the extent that securities are held in the name of UMB Bank or U.S. or non-U.S. sub custodians in a securities depository, clearing agency or omnibus customer account of such custodian. In consideration for these services, the Fund pays UMB Bank an asset based fee.

**Chief Compliance Officer –** Vigilant Compliance, LLC ("Vigilant") provides Chief Compliance Officer ("CCO") services to the Fund. An officer of the Fund is an employee of Vigilant.

**Guarantees and Indemnification –** In the normal course of business, the Fund enters into contracts with service providers that contain general indemnification clauses. The Fund's maximum exposure under these arrangements is unknown, as this would involve future claims against the Fund that have not yet occurred. Based on experience, the Fund expects the risk of loss to be remote.

**7. CAPITAL CONTRIBUTIONS AND WITHDRAWALS**

The Fund will generally offer Shares for purchase as of the first business day of each calendar quarter, except that Shares may be offered more or less frequently as determined by the Board in its sole discretion. The Board may also suspend or terminate offerings of Shares at any time.

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 23 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

**7. CAPITAL CONTRIBUTIONS AND WITHDRAWALS** (Continued)

A substantial portion of the Fund's investments are illiquid. For this reason, the Fund is structured as a closed-end fund, which means that the shareholders will not have the right to redeem their Shares on a daily basis. In addition, the Fund does not expect any trading market to develop for the Shares. As a result, if investors decide to invest in the Fund, they will have very limited opportunity to sell their Shares. At the discretion of the Board and provided that it is in the best interests of the Fund and the shareholders to do so, the Fund intends to provide a limited degree of liquidity for the shareholders by conducting repurchase offers generally quarterly with a valuation date on or about March 31, June 30, September 30 and December 31 of each year. Each repurchase offer ordinarily will be limited to the repurchase of approximately 5% of the Shares outstanding, but if the value of Shares tendered for repurchase exceeds the value the Fund intended to repurchase, the Fund may determine to repurchase less than the full number of Shares tendered. In such event, shareholders will have their Shares repurchased on a pro rata basis, and tendering shareholders will not have all of their tendered Shares repurchased by the Fund. No shareholder will have the right to require the Fund to redeem its Shares.

**8. FEDERAL TAX INFORMATION**

At March 31, 2026, the cost of investments on a tax basis and gross unrealized appreciation/(depreciation) on investments for federal income tax purposes were as follows:

---

| | |
|:---|:---|
|  Cost of investments  | $106873747 |
|  Gross unrealized appreciation  | 53923768 |
|  Gross unrealized depreciation  | (13614134) |
|  Net unrealized appreciation on investments  | $40309634 |

---

The difference between cost amounts for financial statement and federal income tax purposes is due primarily to timing differences in recognizing certain gains and losses on investments.

U.S. GAAP requires that certain components of net assets be reclassified between financial and tax reporting. These reclassifications have no effect on net assets or NAV per share. Permanent differences in book and tax accounting are attributable to differences in consolidation of the Subsidiary for the tax year ended September 30, 2025, and to non-deductible deferred income tax expenses for the fiscal year ended March 31, 2026. The following amounts have been reclassified to paid-in capital and total distributable earnings.

---

| | | |
|:---|:---|:---|
|  | **Increase (Decrease)** | **Increase (Decrease)** |
|  | **Paid-In Capital** | **Total Distributable<br>Earnings (Loss)** |
|  Tax Year Ended September 30, 2025 | $(663690) | $663690 |
|  Fiscal Year Ended March 31, 2026 | (237213) | 237213 |

---

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 24 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

8. FEDERAL TAX INFORMATION (Continued)

As of September 30, 2025, the components of accumulated earnings/(losses) on a tax basis were as follows:

---

| | |
|:---|:---|
|  Undistributed ordinary income | $— |
|  Undistributed long-term capital gains | 6805216 |
|  Tax Accumulated earnings | 6805216 |
|  Accumulated capital and other losses | (6497564) |
|  Unrealized appreciation on investments | 47323410 |
|  Total distributable earnings | $47631062 |

---

The tax character of distributions is disclosed for the Fund's tax year, not the fiscal year, as it represents final and accurate information. The estimated tax character of the distributions paid by the Fund during the tax years ended September 30, 2025 and September 30, 2024 is as follows:

---

| | | |
|:---|:---|:---|
|  | **Tax Year Ended <br>September 30, <br>2025** | **Tax Year Ended <br>September 30, <br>2024** |
|  Distributions paid from: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Ordinary income | $4313028 | $120994 |
| &nbsp;&nbsp;&nbsp;&nbsp; Long-term Gain | 12121042 | 2294977 |
|  Total taxable distributions | 16434070 | 2415971 |
|  Total distributions paid | $**16434070** | $**2415971** |

---

The current taxes reflect the estimated tax liability of the Fund as of March 31, 2026, based on taxable income of the Subsidiary. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities of the Subsidiary for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is recognized if, based on the weight of the available evidence, it is more likely than not that all of the deferred income tax asset will not be realized.

As of March 31, 2026, the Fund recorded a net deferred tax liability for the investments of the Subsidiary. Should a net deferred tax asset exist in the future, the Fund will assess whether a valuation allowance should be booked to reserve against that asset.

The Fund's current and deferred tax (expense)/benefit as of March 31, 2026 consist of the following:

---

| | |
|:---|:---|
|  Current Tax (Expense) Benefit |  |
| &nbsp;&nbsp; Federal  | $11030 |
| &nbsp;&nbsp; State  | 38611 |
|  Total Current Tax (Expense) Benefit  | 49641 |
|  Deferred Tax (Expense) Benefit |  |
| &nbsp;&nbsp; Federal  | (249187) |
| &nbsp;&nbsp; State  | (37667) |
|  Total Deferred Tax (Expense) Benefit  | (286854) |
|  Total Income Tax (Expense) Benefit  | $**(237213)** |

---

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 25 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

8. FEDERAL TAX INFORMATION (Continued)

Components of the Fund's deferred tax assets and liabilities are as follows:

---

| | |
|:---|:---|
|  Deferred tax liability |  |
| &nbsp;&nbsp; Net unrealized gain on investments  | $(512104) |
|  Net Deferred Tax Asset/(Liability)  | $(512104) |

---

Currently, the federal income tax rate for a corporation is 21% and blended state tax rate net of Federal benefit is 4.40%. Total income tax (expense)/benefit (current and deferred) differs from the amount computed by applying the federal and state statutory income tax rates to net investment income and realized and unrealized gain/(losses) on investment before taxes as follows:

---

| | | |
|:---|:---|:---|
|  | | **Percent** |
|  Federal income tax (expense)/benefit at statutory rate | $(275010) | 21.00% |
|  State income tax (expense)/benefit (net of federal benefit)<sup>(1)</sup> | (57566) | 4.40% |
|  Nontaxable or nondeductible items | (189) | 0.01% |
|  Prior period provision to return adjustments | (463) | 0.04% |
|  Effect of changes in tax rates during current period | 96015 | (7.33)% |
|  Net income Tax (Expense) Benefit | (237213) | 18.12% |

---

<sup>(1)</sup> State taxes in North Dakota, Montana and Wisconsin made up the majority (greater than 50 percent) of the tax effect in this category.

As it pertains to the Subsidiary, the utilization of net operating losses in future years is limited to the lesser of all available net operating losses or 80% of taxable income before net operating loss utilization. For the tax year ended September 30, 2025, the Subsidiary expects to utilize $18,386 of net operating losses.

As it pertains to the Subsidiary, capital losses incurred during the year by a C corporation can be carried back three years or forward five years. The Subsidiary did not utilize or defer any capital losses during the tax year ended September 30, 2025.

**9. INVESTMENT TRANSACTIONS**

For the year ended March 31, 2026, the total purchases and total distribution proceeds from sale, redemption or other disposition of investments, excluding short-term investments, amounted to $15,594,567 and $28,360,897, respectively.

**10. NEW ACCOUNTING PRONOUNCEMENTS**

**In the reporting period, the Fund adopted FASB Accounting Standards Update 2023**-09**, Income Taxes (Topic 740) – Improvements to Income Tax Disclosures (ASU 2023**-09**), which enhances income tax disclosures, including disclosure income taxes paid disaggregated by jurisdiction. The new requirements, including the disaggregation of income taxes paid by jurisdiction, are reflected in these financial statements.**

**11. SUBSEQUENT EVENTS**

The Fund has evaluated the events and transactions through the date the financial statements were issued and determined there were no subsequent events that required adjustment to or disclosure in the financial statements.

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 26 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

#### ASPIRIANT CAPITAL APPRECIATION FUND<br>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Shareholders and Board of Trustees of<br>Aspiriant Capital Appreciation Fund

<u><u>Opinion on the Financial Statements</u></u>

We have audited the accompanying consolidated statement of assets and liabilities, including the consolidated schedule of investments, of Aspiriant Capital Appreciation Fund (formerly known as Aspiriant Risk-Managed Capital Appreciation Fund, the "Fund") as of March 31, 2026, the related consolidated statements of operations and cash flows for the year then ended, the consolidated statements of changes in net assets for each of the two years in the period then ended, the financial highlights (consolidated as applicable) for each of the five years in the period then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Fund as of March 31, 2026, the results of its operations and its cash flows for the year then ended, the changes in net assets for each of the two years in the period then ended, and the financial highlights for each of the five years in the period then ended, in conformity with accounting principles generally accepted in the United States of America.

<u><u>Basis for Opinion</u></u>

These financial statements are the responsibility of the Fund's management. Our responsibility is to express an opinion on the Fund's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Fund in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement whether due to error or fraud.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our procedures included confirmation of securities owned as of March 31, 2026, by correspondence with the custodians and underlying issuers. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

We have served as the Fund's auditor since 2021.

![](tcohen_sig.jpg)

COHEN & COMPANY, LTD.<br>Philadelphia, Pennsylvania<br>May 29, 2026

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 27 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

#### ASPIRIANT CAPITAL APPRECIATION FUND<br>OTHER INFORMATION<br> March 31, 2026 (Unaudited)
**BOARD CONSIDERATION OF THE INVESTMENT MANAGEMENT AGREEMENT**

At a meeting of the Board of Trustees (the "Board") held on December 2, 2025 and December 3, 2025 (the "Meeting"), by a unanimous vote, the Board, including a majority of Trustees who are not "interested persons" within the meaning of Section 2(a)(19) of the Investment Company Act (the "Independent Trustees"), approved the continuation of the Investment Management Agreement between Aspiriant, LLC (the "Investment Manager") and the Fund.

In advance of the Meeting, the Independent Trustees requested and received materials from the Investment Manager to assist them in considering the approval of the Investment Management Agreement. The Independent Trustees reviewed reports from third parties and management about the below factors, including a fund comparison report compiled by an independent third-party provider of investment company data, that included information comparing the Fund's performance, fees and expenses with those of a group of peer funds selected by the independent third-party provider. The Board did not consider any single factor as controlling in determining whether to approve the Investment Management Agreement nor are the items described herein all-encompassing of the matters considered by the Board.

The Board engaged in a detailed discussion of the materials with management of the Investment Manager. The Independent Trustees then met separately with independent counsel to the Independent Trustees for a full review of the materials. Following this session, the full Board reconvened and after further discussion determined that the information presented provided a sufficient basis upon which to approve the Investment Management Agreement.

<u><u>NATURE, EXTENT AND QUALITY OF SERVICES</u></u>

The Board reviewed and considered the nature and extent of the investment management services provided by the Investment Manager to the Fund under the Investment Management Agreement, including the selection of Fund investments. The Board also reviewed and considered the nature and extent of the non-advisory, administrative services provided by the Investment Manager to the Fund, including, among other things, providing office facilities, equipment, and personnel. The Board reviewed and considered the qualifications of the portfolio managers and other key personnel of the Investment Manager who provide the investment management and administrative services to the Fund. The Board determined that the Investment Manager's portfolio managers and key personnel are well-qualified by education and/or training and experience to perform the services for the Fund in an efficient and professional manner. The Board also took into account the Investment Manager's compliance policies and procedures, including the procedures used to determine the value of the Fund's investments. The Board concluded that the overall quality of the advisory and administrative services provided to the Fund by the Investment Manager was satisfactory.

<u><u>PERFORMANCE</u></u>

The Board considered the investment performance of the Investment Manager with respect to the Fund. The Board considered the performance of the Fund as compared to the performance of several key indices for each year since the Fund's inception, as well as the one- and three-year periods through June 30, 2025. The Board also considered the overall performance of the Fund, noting that the Investment Manager did not currently manage any other funds with similar investment objectives and strategies as the Fund. The Board further considered performance information of the Fund relative to performance information provided for comparable peer funds identified within the FUSE Report. The Board concluded that, on the basis of the information provided within the FUSE Report, that the Fund's performance was satisfactory and within the range of comparable peer funds identified.

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 28 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

#### ASPIRIANT CAPITAL APPRECIATION FUND<br>OTHER INFORMATION (Continued)<br> March 31, 2026 (Unaudited)
**BOARD CONSIDERATION OF THE INVESTMENT MANAGEMENT AGREEMENT (Continued)**

<u><u>FEES AND EXPENSES</u></u>

The Board reviewed the advisory fee rate and total expense ratio of the Fund. The Board compared the advisory fees and total expense ratio of the Fund with various comparative data provided within the FUSE Report. The Board noted that the advisory fees were lower than the advisory fees payable by other comparable peer funds identified. In addition, the Board noted that the Investment Manager waives part of its management fee pursuant to a contractual agreement. The Board concluded that the advisory fees paid by the Fund were lower than the comparable peer funds identified and reasonable and satisfactory in light of the services provided.

<u><u>BREAKPOINTS AND ECONOMIES OF SCALE</u></u>

The Board reviewed the structure of the Fund's investment management fee under the Investment Management Agreement, noting that there were no breakpoints. The Board considered the Fund's advisory fees and concluded that the fees were reasonable and satisfactory in light of the services provided. The Board also determined that, given the Fund's current size, economies of scale were not present at this time.

<u><u>PROFITABILITY OF INVESTMENT ADVISER</u></u>

The Board considered and reviewed information concerning the costs incurred and profits realized by the Investment Manager from its relationship with the Fund. The Board also reviewed the Investment Manager's financial condition and noted that the financial condition appeared stable. The Board determined that the advisory fees and the compensation to the Investment Manager was reasonable, and the financial condition was adequate.

<u><u>ANCILLARY BENEFITS AND OTHER FACTORS</u></u>

The Board also discussed other benefits to be received by the Investment Manager from its management of the Fund including, without limitation, the ability to market its advisory services for similar products in the future. The Board noted that the Investment Manager did not have affiliations with the Fund's transfer agent, fund accountant, custodian, or distributor and, therefore, did not derive any benefits from the relationships these parties may have with the Fund. The Board concluded that the advisory fees were reasonable in light of the fall-out benefits.

<u><u>GENERAL CONCLUSION</u></u>

Based on its consideration of all factors that it deemed material, and assisted by the advice of its counsel, the Board concluded it would be in the best interest of the Fund and its shareholders to approve the continuance of the Investment Management Agreement.

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 29 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

**PROXY VOTING POLICIES AND PROCEDURES**

For a description of the policies and procedures that the Fund uses to determine how to vote proxies relating to portfolio securities, please call 1-877-997-9971 and request a Statement of Additional Information. One will be mailed to you free of charge. The Statement of Additional Information is also available on the website of the U.S. Securities and Exchange Commission at www.sec.gov as well as the Fund's website at www.aspiriantfunds.com.

Information on how the Fund voted proxies relating to portfolio securities during the 12-month period ended June 30 is available without charge, upon request, by calling 1-877-997-9971 or by accessing the website of the U.S. Securities and Exchange Commission.

**DISCLOSURE OF PORTFOLIO HOLDINGS**

The Fund files complete schedule of portfolio holdings with the U.S. Securities and Exchange Commission for the first and third quarters of each fiscal year on Form N-PORT. The Fund's Forms N-PORT are available on the website of the U.S. Securities and Exchange Commission at www.sec.gov, and may also be reviewed and copied at the Commission's Public Reference Room in Washington, DC. Information on the operation of the Public Reference Room may be obtained by calling 1-800-SEC-0330.

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 30 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

#### ASPIRIANT CAPITAL APPRECIATION FUND<br>FUND MANAGEMENT<br> March 31, 2026 (Unaudited)
**The members of the Board and the Fund's officers and their brief biographical information, including their addresses, their year of birth and descriptions of their principal occupations during the past five years, are set forth below. The Fund's Statement of Additional Information includes additional information about the membership of the Board, and is available without charge, upon request, by calling the Fund at (877) 997**-9971**.**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  **INDEPENDENT TRUSTEES** | **INDEPENDENT TRUSTEES** | **INDEPENDENT TRUSTEES** | **INDEPENDENT TRUSTEES** | **INDEPENDENT TRUSTEES** | **INDEPENDENT TRUSTEES** |
|  **<br>NAME, ADDRESS <br>AND YEAR <br>OF BIRTH** | **POSITION(S) <br>HELD WITH <br>THE FUND** | **TERM OF <br>OFFICE <br>AND <br>LENGTH <br>OF TIME <br>SERVED\*** | **<br>PRINCIPAL OCCUPATION(S)<br>DURING PAST FIVE YEARS** | **NUMBER OF <br>PORTFOLIOS <br>IN FUND <br>COMPLEX\*\* <br>OVERSEEN <br>BY TRUSTEE** | **OTHER <br>DIRECTORSHIPS <br>HELD BY <br>TRUSTEES\*\*\*** |
|  David G. Lee <br>Year of Birth: 1952 <br> c/o UMB Fund <br>Services, Inc. <br>235 W. Galena St. <br>Milwaukee, <br>WI 53212 | Chairman and Trustee | Chairman since May 2019; Trustee since Inception | Retired (Since 2012); President and Director, Client Opinions, Inc. (2003 – 2012); Chief Operating Officer, Brandywine Global Investment Management (1998 – 2002). | 33 |  |
|  Robert Seyferth <br>Year of Birth: 1952 <br> c/o UMB Fund <br>Services, Inc. <br>235 W. Galena St. <br>Milwaukee, <br>WI 53212 | Trustee | Since Inception | Retired (Since 2009); Chief Procurement Officer/Senior Managing Director, Bear Stearns/JP Morgan Chase (1993 – 2009). | 33 |  |
|  Gary E. Shugrue <br>Year of Birth: 1954 <br> c/o UMB Fund <br>Services, Inc. <br>235 W. Galena St. <br>Milwaukee, <br>WI 53212 | Trustee | Since September 2021 | Retired (Since 2023); Managing Director, Veritable LP (investment advisory firm) (2016-2023); Founder/Chief Investment Officer, Ascendant Capital Partners, LP (private equity firm) (2003 – 2018). | 33 | Trustee, Quaker Investment Trust (1 portfolio) (registered investment company).  |

---

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 31 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

#### ASPIRIANT CAPITAL APPRECIATION FUND<br>FUND MANAGEMENT (Continued)<br> March 31, 2026 (Unaudited)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  **INTERESTED TRUSTEE AND OFFICERS** | **INTERESTED TRUSTEE AND OFFICERS** | **INTERESTED TRUSTEE AND OFFICERS** | **INTERESTED TRUSTEE AND OFFICERS** | **INTERESTED TRUSTEE AND OFFICERS** | **INTERESTED TRUSTEE AND OFFICERS** |
|  **<br>NAME, ADDRESS <br>AND YEAR <br>OF BIRTH** | **POSITION(S) <br>HELD WITH <br>THE FUND** | **TERM OF <br>OFFICE <br>AND <br>LENGTH <br>OF TIME <br>SERVED\*** | **<br>PRINCIPAL OCCUPATION(S)<br>DURING PAST FIVE YEARS** | **NUMBER OF <br>PORTFOLIOS <br>IN FUND <br>COMPLEX\*\* <br>OVERSEEN <br>BY TRUSTEE** | **OTHER <br>DIRECTORSHIPS <br>HELD BY <br>TRUSTEES\*\*\*** |
|  Terrance P. Gallagher\*\*\*\* <br>Year of Birth: 1958 <br> c/o UMB Fund Services, Inc. <br>235 W. Galena St. Milwaukee, <br>WI 53212 | Trustee | Since June 2020 | Retired (Since October 2025); Trustee, Investment Managers Series Trust II (registered investment company) (2013 – Present); Executive Vice President and Trust Platform Director, UMB Fund Services, Inc. (2024 – October 2025); President, Investment Managers Series Trust II (registered investment company) (2013 – April 2025); Executive Vice President and Director of Fund Accounting, Administration and Tax, UMB Fund Services, Inc. (2007 – 2023). | 33 | Trustee, Investment Managers Series Trust II (262 portfolios) (registered investment company). |
|  Benjamin Schmidt Year of Birth: 1976 <br> c/o UMB Fund Services, Inc. <br>235 W. Galena St. Milwaukee, <br>WI 53212 | President Treasurer | Since August 2024 From April 2021 – August 2024 | Director, Aspiriant, LLC (2015 – present); Assistant Treasurer; Chief Compliance Officer; Anti-Money Laundering Officer, Aspiriant Trust (2015 – Present). | N/A | N/A |
|  Laura Boucher <br>Year of Birth: 1981 | Treasurer | Since August 2024 | Senior Manager, Fund Administration, Aspiriant, LLC (2015 – Present). | N/A | N/A |
|  c/o UMB Fund Services, Inc. <br>235 W. Galena St. Milwaukee, <br>WI 53212 | Assistant Treasurer | From April 2021 – August 2024 |  |  |  |
|  Jason Stujenske Year of Birth: 1985 <br> c/o UMB Fund Services, Inc. <br>235 W. Galena St. Milwaukee, <br>WI 53212 | Assistant Treasurer | Since August 2024 | Manager, Fund Administration, Aspiriant, LLC (2016 – Present). | N/A | N/A |

---

------

---

| | |
|:---|:---|
|  ![](taspiriant_logo2.jpg) | 32 |
|  ![](tbar_001.jpg) | ![](tbar_001.jpg) |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  **INTERESTED TRUSTEE AND OFFICERS** | **INTERESTED TRUSTEE AND OFFICERS** | **INTERESTED TRUSTEE AND OFFICERS** | **INTERESTED TRUSTEE AND OFFICERS** | **INTERESTED TRUSTEE AND OFFICERS** | **INTERESTED TRUSTEE AND OFFICERS** |
|  **<br>NAME, ADDRESS <br>AND YEAR <br>OF BIRTH** | **POSITION(S) <br>HELD WITH <br>THE FUND** | **TERM OF <br>OFFICE <br>AND <br>LENGTH <br>OF TIME <br>SERVED\*** | **<br>PRINCIPAL OCCUPATION(S)<br>DURING PAST FIVE YEARS** | **NUMBER OF <br>PORTFOLIOS <br>IN FUND <br>COMPLEX\*\* <br>OVERSEEN <br>BY TRUSTEE** | **OTHER <br>DIRECTORSHIPS <br>HELD BY <br>TRUSTEES\*\*\*** |
|  Bernadette Murphy Year of Birth: 1964 <br> c/o UMB Fund Services, Inc. <br>235 W. Galena St. <br>Milwaukee, <br>WI 53212 | Chief Compliance Officer | Since Inception | Director, Vigilant Compliance, LLC (investment management services firm) (2018 – Present). | N/A | N/A |
|  Ann Maurer <br>Year of Birth: 1972 <br> c/o UMB Fund Services, Inc. <br>235 W. Galena St. Milwaukee, <br>WI 53212 | Secretary | Since Inception | Senior Vice President, Registered Fund Product Manager (August 2025 – Present), Senior Vice President, Client Services (2017 – 2025); Vice President, Senior Client Service Manager (2013 – 2017); Assistant Vice President, Client Relations Manager (2002 – 2013); UMB Fund Services, Inc. | N/A | N/A |

---

---

| | |
|:---|:---|
|  \* | Trustees serve on the Board for terms of indefinite duration. A Trustee's position in that capacity will terminate if the Trustee is removed or resigns or, among other events, upon the Trustee's death, incapacity or retirement. Officers hold office until their successors are chosen and qualified and serve at the pleasure of the Trustees. |
|  \*\* | As of March 31, 2026, the fund complex consists of the AFA Asset Based Lending Fund, Agility Multi-Asset Income Fund, Aspiriant Capital Appreciation Fund, Aspiriant Real Assets Fund, Destiny Alternative Fund, Felicitas Income Fund, Felicitas Private Markets Fund, First Trust Alternative Opportunities Fund, First Trust Enhanced Private Credit Fund, First Trust Hedged Strategies Fund, First Trust Private Assets Fund, First Trust Private Credit Fund, First Trust Real Assets Fund, FT Vest Hedged Equity Income Fund: Series A2, FT Vest Hedged Equity Income Fund: Series A3, FT Vest Hedged Equity Income Fund: Series A4, FT Vest Hedged Equity Income Fund: Series B1, FT Vest Hedged Equity Income Fund: Series B2, FT Vest Hedged Equity Income Fund: Series B3, FT Vest Rising Dividend Achievers Total Return Fund, FT Vest Total Return Income Fund: Series A1, FT Vest Total Return Income Fund: Series A2, FT Vest Total Return Income Fund: Series A3, FT Vest Total Return Income Fund: Series A4, FT Vest Total Return Income Fund: Series B1, FT Vest Total Return Income Fund: Series B2, FT Vest Total Return Income Fund: Series B3, FT Vest Total Return Income Fund: Series B4, Infinity Core Alternative Fund, Pender Real Estate Credit Fund, Variant Alternative Income Fund, Variant Alternative Lending Fund and Variant Impact Fund. |
|  \*\*\* | As of March 31, 2026. |
|  \*\*\*\* | Mr. Gallagher is deemed an interested person of the Fund because of his affiliation with the Fund's Administrator. |

---

------

---

| |
|:---|
|  ![](taspiriant_logo2.jpg) |
|  ![](tbar_001.jpg) |

---

#### ASPIRIANT CAPITAL APPRECIATION FUND

#### INVESTMENT MANAGER <br> Aspiriant, LLC<br>11100 Santa Monica Blvd., Suite 600 <br>Los Angeles, CA 90025

#### INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM <br>Cohen & Company, Ltd.<br>1835 Market Street, Suite 310<br>Philadelphia, PA 19103

#### FUND COUNSEL <br>Faegre Drinker Biddle & Reath LLP<br>One Logan Square, Ste. 2000<br>Philadelphia, PA 19103-6996

#### CUSTODIAN BANK <br>UMB Bank, n.a.<br>928 Grand Blvd.<br>Kansas City, MO 64106

#### TRANSFER AGENT / ADMINISTRATOR <br>UMB Fund Services, Inc.<br>235 West Galena Street<br>Milwaukee, WI 53212

#### DISTRIBUTOR
Distribution Services, LLC<br>190 Middle Street, Suite 301<br>Portland, ME 04101

(b) Not applicable.

**Item 2. Code of Ethics.**

(a) The registrant, as of the end of the period covered by this report, has adopted a code of ethics that
applies to the registrant's principal executive officer, principal financial officer, principal accounting officer or controller,
or persons performing similar functions, regardless of whether these individuals are employed by the registrant or a third party.

(b) Not applicable.

(c) There have been no amendments, during the period covered by this report, to a provision of the code of
ethics that applies to the registrant's principal executive officer, principal financial officer, principal accounting officer or
controller, or persons performing similar functions, regardless of whether these individuals are employed by the registrant or a third
party, and that relates to any element of the code of ethics description.

(d) The registrant has not granted any waivers, during the period covered by this report, including an implicit
waiver, from a provision of the code of ethics that applies to the registrant's principal executive officer, principal financial
officer, principal accounting officer or controller, or persons performing similar functions, regardless of whether these individuals
are employed by the registrant or a third party, that relates to one or more of the items set forth in paragraph (b) of this Item's
instructions.

(e) Not applicable.

(f) The registrant has included with this filing, pursuant to Item 19(a)(1), a copy of its code of ethics
that applies to the registrant's principal executive officer, principal financial officer, principal accounting officer or controller,
or persons performing similar functions, as an exhibit to its annual report on this Form N-CSR.

**Item 3. Audit Committee Financial Expert.**

(a)(1) The registrant's board of trustees has determined that the registrant has at least one audit committee financial expert serving on the audit committee.

(a)(2) As of the end of the period covered by the report, the registrant's board of trustees has determined that Mr. David G. Lee and Mr. Robert Seyferth are qualified to serve as the audit committee financial experts serving on its audit committee and that they are "independent," as defined in Form N-CSR Item 3(a)(2).

(a)(3) Not applicable.

**Item 4. Principal Accountant Fees and Services.**

(a) Audit Fees. The aggregate fees billed for each of the last two fiscal years for professional services rendered by the principal accountant for the audit of the registrant's annual financial statements or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for those fiscal years are as follows:

---

| | |
|:---|:---|
| Fiscal year ended March 31, 2025 | $55000 |
| Fiscal year ended March 31, 2026 | $55000 |

---

(b) Audit-Related Fees. The aggregate fees billed in each of the last two fiscal years for assurance and related services by the principal accountant that were reasonably related to the performance of the audit of the registrant's financial statements and are not reported under paragraph (a) of this Item.

---

| | |
|:---|:---|
| Fiscal year ended March 31, 2025 |  |
| Fiscal year ended March 31, 2026 | $43 |

---

(c) Tax Fees. The aggregate fees billed in each of the last two fiscal years for professional services rendered by the principal accountant for tax compliance, tax advice, and tax planning. The tax services provided include review and signing of the registrant's income and excise tax returns, and review of excise distribution calculations.

---

| | |
|:---|:---|
| Fiscal year ended March 31, 2025 | $30650 |
| Fiscal year ended March 31, 2026 | $42500 |

---

(d) All Other Fees. The aggregate fees billed in each of the last two fiscal years for products and services provided by the registrant's principal accountant, other than the services reported in paragraphs (a) through (c) of this Item.

Fiscal year ended March 31, 2025 None <br> Fiscal year ended March 31, 2026 None

(e) Audit Committee's pre-approval policies and procedures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Audit Committee has adopted pre-approval policies and procedures that require the Audit Committee to pre-approve all audit and non-audit services of the registrant, including services provided to the registrant's investment adviser or any entity controlling, controlled by or under common control with the registrant's investment adviser that provides ongoing services to the registrant with respect to any engagement that directly relates to the operations and financial reporting of the registrant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) None of the principal accountant's fees or services described in each of paragraphs (b) through (d) of this Item were approved by the audit committee pursuant to the waiver provision of paragraph (c)(7)(i)(C) of Rule 2-01 of Regulation S-X.

(f) Less than 50% of the hours expended on the principal accountant's engagement to audit the registrant's financial statements for the most recent fiscal year were attributed to work performed by persons other than the principal accountant's full-time, permanent employees.

(g) The aggregate non-audit fees billed by the registrant's principal accountant for services rendered to the registrant, and rendered to the registrant's investment adviser (not including any sub-adviser whose role is primarily portfolio management and is subcontracted with or overseen by another investment adviser), and any entity controlling, controlled by, or under common control with the adviser that provides ongoing services to the registrant for the past two fiscal years.

---

| | |
|:---|:---|
| Fiscal year ended March 31, 2025 | $30650 |
| Fiscal year ended March 31, 2026 | $42500 |

---

(h) The registrant's audit committee of the board of trustees has considered whether the provision of non-audit services that were rendered to the registrant's investment adviser (not including any sub-adviser whose role is primarily portfolio management and is subcontracted with or overseen by another investment adviser), and any entity controlling, controlled by, or under common control with the investment adviser that provides ongoing services to the registrant that were not pre-approved pursuant to paragraph (c)(7)(ii) of Rule 2-01 of Regulation S-X is compatible with maintaining the principal accountant's independence.

(i) Not applicable.

(j) Not applicable.

**Item 5. Audit Committee of Listed Registrants.**

Not applicable.

**Item 6. Investments.**

(a) Included as part of the report to shareholders filed under Item 1 of this Form N-CSR.

(b) Not applicable.

**Item 7. Financial Statements and Financial Highlights for Open-End Management Investment Companies.**

Not applicable.

**Item 8. Changes in and Disagreements with Accountants for Open-End Management Investment Companies.**

Not applicable.

**Item 9. Proxy Disclosures for Open-End Management Investment Companies.**

Not applicable.

**Item 10. Remuneration Paid to Directors, Officers, and Others of Open-End Management Investment Companies.**

Not applicable.

**Item 11. Statement Regarding Basis for Approval of Investment Advisory Contract.**

The registrant's statement regarding the basis for approval of the investment advisory contract is included as part of the Reports to Stockholders filed under item 1(a) of this Form.

**Item 12. Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies.**

The Fund invests substantially all of its investable assets in Investment Funds. While it is unlikely that the Fund will receive notices or proxies from Investment Funds (or receives proxy statements or similar notices in connection with any other portfolio securities), to the extent that the Fund does receive such notices or proxies and the Fund has voting interests in such Investment Funds, the Board has delegated responsibility for decisions regarding proxy voting for securities held by the Fund to the Investment Manager. The Investment Manager will vote such proxies in accordance with its proxy policies and procedures.

The Investment Manager's proxy policies and procedures require that the Investment Manager vote proxies received in a manner reasonably believed to be in the best interests of the Fund and its shareholders and not affected by any material conflict of interest. The Investment Manager considers shareholders' best economic interests over the long term (i.e., considers the common interest of all shareholders over time). Although shareholders may have differing political or social interests or values, their economic interest is generally uniform.

The Investment Manager has adopted proxy voting guidelines to assist in making voting decisions on common issues. The guidelines are designed to address those securities in which the Fund generally invests and may be revised in the Investment Manager's discretion. Any non-routine matters not addressed by the proxy voting guidelines are addressed on a case-by-case basis, taking into account all relevant facts and circumstances at the time of the vote, particularly where such matters have a potential for major economic impact on the issuer's structure or operations. In making voting determinations, the Investment Manager may conduct research internally and/or use the resources of an independent research consultant. The Investment Manager may also consider other materials such as studies of corporate governance and/or analyses of shareholder and management proposals by a certain sector of companies and may engage in dialogue with an issuer's management.

The Investment Manager acknowledges its responsibility to identify material conflicts of interest related to voting proxies. The Investment Manager's employees are required to disclose to the Investment Manager's chief compliance officer any personal conflicts, such as officer or director positions held by them, their spouses or close relatives, in any publicly traded company. Conflicts based on business relationships with the Investment Manager or any affiliate will be considered only to the extent that the Investment Manager has actual knowledge of such relationships. The Investment Manager then takes appropriate steps to address identified conflicts.

In some cases, the cost of voting a proxy may outweigh the expected benefits. For example, casting a vote on a foreign security may involve additional costs such as hiring a translator or traveling to the foreign country to vote the security in person. The Investment Manager may abstain from voting a proxy if the effect on shareholders' economic interests or the value of the portfolio holding is indeterminable or insignificant.

In certain cases, securities on loan as part of a securities lending program may not be voted. Nothing in the proxy voting policies shall obligate the Investment Manager to exercise voting rights with respect to a portfolio security if it is prohibited by the terms of the security or by applicable law or otherwise.

The Investment Manager will not discuss with members of the public how it intends to vote on any particular proxy proposal.

The Fund will be required to file Form N-PX, with its complete proxy voting record for the twelve months ended June 30, no later than August 31 of each year. The Fund's Form N-PX filing will be available: (i) without charge, upon request, by calling the Fund at (877) 997-9971 or (ii) by visiting the SEC's website at https://www.sec.gov.

**Item 13. Portfolio Managers of Closed-End Management Investment Companies.**

(a)(1) Identification of Portfolio Manager(s) or Management Team Members and Description of Role of Portfolio Manager(s) or Management Team Members

The following is biographical information about the members of Aspiriant, LLC (the "Investment Manager"), who are primarily responsible for the day-to-day portfolio management of the Aspiriant Capital Appreciation Fund as of June 5, 2026 are below:

**John Allen, CFA**

Mr. Allen is Chief Investment Officer ("CIO") at the Investment Manager. Mr. Allen joined the Investment Manager as CIO in 2014. Prior to joining the Investment Manager, he was a senior member of the client service team at Grantham, Mayo, Van Otterloo ("GMO") from 2009 to 2014. Prior to joining GMO, Mr. Allen was Head of Investments at a large family office. He began working in the financial services industry in the investment banking department at Donaldson, Lufkin & Jenrette and business consulting practice of Stern Stewart & Company. Mr. Allen is a graduate of the University of Virginia.

**Marc Castellani, CFA, CAIA, CIMA**

Mr. Castellani is Managing Director in Private Investments and Chari of the Board of Directors at the Investment Manager. Mr. Castellani joined the Investment Manager in 2015. Prior to joining the Investment Manager, he worked at J.P. Morgan Private Bank in Los Angeles from 2012 to 2015. Prior to joining J.P. Morgan Private Bank, he worked at U.S. Trust from 2010 to 2012. Previously, Mr. Castellani was a senior investment banker in the Merger and Acquisitions departments of J.P. Morgan and Banc of America Securities. He began his career in the financial services industry as an Associate in the corporate finance advisory practice of Stern Stewart & Company. Mr. Castellani is a graduate of Cornell University and holds a M.B.A from the University of Rochester.

**Stephen Kawasaki, CFA, CAIA, CFP**

Mr. Kawasaki is a Director of Investment Strategy & Research at the Investment Manager. Prior to joining Aspiriant in 2016, Mr. Kawasaki was a member of the Investment Committee at Balasa Dinverno Foltz LLC, which manages assets primarily for individuals, families, and institutional clients. In addition to investment strategy responsibilities, he provided investment and wealth advisory services to high-net-worth individuals and families. Mr. Kawasaki earned a Bachelor of Science degree in Financial Planning from the University of Illinois.

(a)(2) Other Accounts Managed by Portfolio Manager(s) or Management Team Member and Potential Conflicts of Interest

The following table provides information about accounts, other than the Fund, of the personnel of Aspiriant, LLC (the "Investment Manager"), who are primarily responsible for the day-to-day portfolio management (the "Portfolio Managers") as of March 31, 2026.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Type of Accounts** | **Total<br> # of<br> Accounts<br> Managed** | **Total Assets<br> ($mm)** | **# of Accounts<br> Managed that<br> Advisory Fee<br> Based on<br> Performance** | **Total Assets<br> that<br> Advisory Fee<br> Based on<br> Performance<br> ($mm)** |
| 1. John Allen | Registered Investment Companies: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5 | $4201 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 |
|  | Other Pooled Investment Vehicles: | 0 | $0 | 0 | $0 |
|  | Other Accounts: | 0 | $0 | 0 | $0 |
| 2. Marc Castellani | Registered Investment Companies: | 5 | $4201 | 0 | $0 |
|  | Other Pooled Investment Vehicles: | 0 | $0 | 0 | $0 |
|  | Other Accounts: | 0 | $0 | 0 | $0 |
| 3. Stephen Kawasaki | Registered Investment Companies: | 0 | $0 | 0 | $0 |
|  | Other Pooled Investment Vehicles: | 0 | $0 | 0 | $0 |
|  | Other Accounts: | 0 | $0 | 0 | $0 |

---

 ****

***Conflicts of Interest***

While the compensation of Portfolio Managers is not tied directly to the performance of a Fund, the Portfolio Managers' management of other accounts may give rise to potential conflicts of interest in connection with their management of a Fund's investments, on the one hand, and the investments of the other accounts, on the other. The other accounts may have the same investment objective as the Fund. Therefore, a potential conflict of interest may arise as a result of the identical investment objectives, whereby the Portfolio Manager could favor one account over another. Another potential conflict could include the Portfolio Managers' knowledge about the size, timing and possible market impact of Fund trades, whereby the Portfolio Manager could use this information to the advantage of other accounts and to the disadvantage of the Fund. However, the Investment Manager has established policies and procedures to ensure that the purchase and sale of securities among all accounts it manages are fairly and equitably allocated. The Investment Manager's trade allocation policy is to aggregate client transactions, including the Fund's, where possible when it is believed that such aggregation may facilitate the Investment Manager's duty of best execution. Client accounts for which orders are aggregated receive the average price of such transaction. Any transaction costs incurred in the transaction are shared pro rata based on each client's participation in the transaction. The Investment Manager generally allocates securities among client accounts according to each account's pre-determined participation in the transaction. The Investment Manager's policy prohibits any allocation of trades that would favor any proprietary accounts, affiliated accounts, or any particular client(s) or group of clients more over any other account(s). The Investment Manager prohibits late trading, frequent trading and/or market timing in the Funds and monitors trades daily to ensure this policy is not violated.

(a)(3) Compensation Structure of Portfolio Manager

As of March 31, 2026, the Portfolio Managers are compensated with base compensation, bonus (a percentage of base compensation), and, if applicable, a share purchase incentive (bonus based on percentage of profit of the Investment Manager divided by shareholders per capita).

(a)(4) Disclosure of Securities Ownership

The following table shows the dollar range of each portfolio manager's beneficial ownership of shares of the Fund as of March 31, 2026:

---

| | |
|:---|:---|
| **Name** | **Dollar Range of Fund Shares Owned** |
| John Allen |  |
| Marc Castellani |  |
| Stephen Kawasaki | $50001-$100000 |

---

(b) Not applicable.

**Item 14. Purchase of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers.**

Not applicable.

**Item 15. Submission of Matters to a Vote of Security Holders.**

The registrant has not made any material changes to the procedures by which shareholders may recommend nominees to the registrant's Board of Trustees.

**Item 16. Controls and Procedures.**

(a) The registrant's principal executive officer and principal financial officer, or persons performing
similar functions, have concluded that the registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment
Company Act of 1940, as amended (the "Act") (17 CFR 270.30a-3(c))) are effective, as of a date within 90 days of the filing
date of this report that includes the disclosure required by this paragraph, based on their evaluation of these controls and procedures
required by Rule 30a-3(b) under the Act (17 CFR 270.30a-3(b)) and Rules 13a-15(b) or 15d-15(b) under the Exchange Act (17 CFR 240.13a-15(b)
or 240.15d-15(b)).

(b) There were no changes in the registrant's internal control over financial reporting (as defined
in Rule 30a-3(d) under the Act (17 CFR 270.30a-3(d)) that occurred during the period covered by this report that materially affected,
or are reasonably likely to materially affect, the registrant's internal control over financial reporting.

**Item 17. Disclosure of Securities Lending Activities for Closed-End Management Investment Companies.**

The Fund did not engage in securities lending activities.

**Item 18. Recovery of Erroneously Awarded Compensation.**

(a) Not applicable.

(b) Not applicable.

**Item 19. Exhibits.**

(a) (1) [Code of ethics, or amendment thereto, that is the subject of the disclosure required by Item 2. *Filed herewith.*](ea029178801_ex99-codeeth.htm)

&nbsp;&nbsp;&nbsp;&nbsp;(2) Not applicable.

&nbsp;&nbsp;&nbsp;&nbsp;(3) [A separate certification for each principal executive and principal financial officer of the registrant as required by Rule 30a-2(a) under the Act (17 CFR 270.30a-2(a)). *Filed herewith.*](ea029178801_ex99-cert.htm)

 

&nbsp;&nbsp;&nbsp;&nbsp;(4) Not applicable.

 

&nbsp;&nbsp;&nbsp;&nbsp;(5) Not applicable.

(b) [Certifications required by Rule 30a-2(b) under the Act (17 CFR 270.30a-2(b)). *Filed herewith.*](ea029178801_ex99-906cert.htm)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| Registrant | **Aspiriant Capital Appreciation Fund** |
| By | /s/ Benjamin Schmidt |
| Title | Benjamin Schmidt, President and<br> Principal Executive Officer |
| Date | 6/5/2026 |

---

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

---

| | |
|:---|:---|
| By | /s/ Benjamin Schmidt |
| Title | Benjamin Schmidt, President and <br> Principal Executive Officer |
| Date | 6/5/2026 |
| By | /s/ Laura Boucher |
| Title | Laura Boucher, Treasurer and <br> Principal Financial Officer |
| Date | 6/5/2026 |

---

## Ex-99.Code

**Exhibit 99.CODE ETH**

**<u>Exhibit R</u>**

**The Aspiriant Risk-Managed Capital Appreciation Fund**

**FINANCIAL OFFICER CODE OF ETHICS**

<u>Purposes of the Code</u>

The reputation and integrity of The Aspiriant Risk-Managed Capital Appreciation Fund (the "Fund") are valuable assets that are vital to the Fund's success. Each officer and employee of the Fund, including each of the Fund's senior financial officers ("SFOs"), is responsible for conducting the Fund's business in a manner that demonstrates a commitment to the highest standards of integrity. SFOs include the principal executive officer, the principal financial officer, comptroller (or principal accounting officer), and any person who performs a similar function. The Fund has adopted a Code of Ethics under Rule 17j-1 under the Investment Company Act of 1940. The Fund's Rule 17j-1 Code is designed to prevent certain conflicts of interest that may arise when officers, employees, or trustees know about present or future Fund transactions, have the power to influence those transactions; and engage in securities transactions in their personal account(s).

The Fund has chosen to adopt a financial officer code of ethics for the purpose of promoting:

&nbsp;&nbsp;&nbsp;&nbsp;· Honest and ethical conduct, including the ethical
handling of actual or apparent conflicts of interest between personal and professional relationships;

&nbsp;&nbsp;&nbsp;&nbsp;· Full, fair, accurate, timely and understandable
disclosure in reports and documents that the Fund files with, or submits to, the SEC, and in other public communications made by the Fund;

&nbsp;&nbsp;&nbsp;&nbsp;· Compliance with applicable laws and governmental
rules and regulations;

&nbsp;&nbsp;&nbsp;&nbsp;· The prompt internal reporting of violations of
the Code to an appropriate person or persons identified in the Code; and

&nbsp;&nbsp;&nbsp;&nbsp;· Accountability for adherence to the Code.

This Code of Ethics should be read in conjunction with the Fund's other policy statements, including its Rule 17j-1 Code and its Disclosure Controls and Procedures.

<u>Principles for the Handling of Financial Information</u> 

The Fund has adopted the following principles to govern the manner in which SFOs perform their duties. Persons subject to these guidelines include the principal executive officer, the principal financial officer, comptroller (or principal accounting officer), and any Fund officer or employee who performs a similar function or who participates in the preparation of any part of the Fund's financial statements. Specifically, persons subject to this Code shall:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Act with honesty and integrity

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Avoid actual or apparent conflicts of interest
with the Fund in personal and professional relationships

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Provide information to the Fund's employees
and service providers (Investment Manager, administrator, outside auditor, outside counsel, custodian, etc.) that is accurate, complete,
objective, relevant, timely, and understandable

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Endeavor to ensure full, fair, timely, accurate,
and understandable disclosure in the Fund's periodic reports

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Comply with the federal securities laws and other
applicable laws and rules, such as the Internal Revenue Code

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Act in good faith, responsibly, and with due
care, competence and diligence, without misrepresenting material facts or subordinating independent judgment to another end

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Respect the confidentiality of information acquired
in the course of their work, except where disclosure is expressly permitted or is otherwise legally mandated

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Record (or participate in the recording of) entries
in the Fund's books and records that are accurate

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Refrain from using confidential information for
personal advantage

<u>Violations of the Code</u>

Any action that directly or indirectly contravenes one or more of the Principles outlined above shall be treated as a violation of this Code unless good cause for such apparent contravention is found to exist.

Dishonest or unethical conduct or conduct that is illegal will constitute a per se violation of this Code, regardless of whether this Code refers to that particular conduct.

A violation of this Code may result in disciplinary action, up to and including termination of employment. The Fund must and will report all suspected criminal violations to the appropriate authorities for possible prosecution, and will investigate, address and report as appropriate, non-criminal violations.

<u>Enforcement of the Code</u>

 

*Violations*

All persons subject to this Code who observe, learn of, or, in good faith, suspect a current or threatened violation of the Code must immediately report the violation in writing to the Compliance Officer, another member of the Fund's senior management, or to the Audit Committee of the Board. An example of a possible Code violation is the preparation and filing of financial disclosure that omits material facts, or that is accurate but is written in a way that obscures its meaning.

 

*Disclosures*

All persons subject to this Code shall file a letter (a "Disclosure Letter") regarding any transaction or relationship that reasonably appears to involve an actual or apparent conflict of interest with the Fund within ten days of becoming aware of such transaction or relationship. A Disclosure Letter should be prepared regarding these transactions or relationships whether you are involved or have only observed the transaction or relationship. All Disclosure Letters shall be submitted to the Compliance Officer, or if it is not possible to disclose the matter to the Compliance Officer, then the Disclosure Letter shall be submitted to another member of the Fund's senior management or to the Audit Committee of the Board.

An executive officer of the Fund or the Audit Committee will review all Disclosure Letters and determine whether further action is warranted. All determinations will be documented in writing and will be maintained by the Compliance Officer or other appropriate officers of the Fund.

 

*Outside Service Providers*

Because service providers to the Fund, such as the Administrator, outside accounting firm, and custodian, provide much of the work relating to the Fund's financial statements, you should be alert for actions by service providers that may be illegal, or that could be viewed as dishonest or unethical conduct. You should report these actions to the Compliance Officer even if you know, or think, that the service provider has its own code of ethics covering persons who are Fund SFOs or employees.

 

*Non-Retaliation Policy*

SFOs who report violations or suspected violations in good faith will not be subject to retaliation of any kind. Reported violations will be investigated and addressed promptly and will be treated confidentially to the extent possible.

<u>Annual Certification</u>

SFOs will receive training on the contents and importance of this Code and related policies and the manner in which violations must be reported and how Disclosure Letters must be submitted. Each SFO will be asked to certify on an annual basis that he/she is in full compliance with the Code and any related policy statements.

<u>Questions about the Code</u>

The Fund's Board of Trustees has designated Bernadette Murphy to be the Compliance Officer for purposes of implementing and administering this Code. Any questions about this Code should be directed to the Compliance Officer.

Effective: December 2020

Revised: April 2024

## Ex-99.Cert

**Exhibit 99.CERT**

**Aspiriant Capital Appreciation Fund**

**Exhibit 19(a)(3) to Form N-CSR**

CERTIFICATIONS PURSUANT TO RULE 30a-2(a) UNDER

THE INVESTMENT COMPANY ACT OF 1940 AND

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Benjamin Schmidt, certify that:

1. I have reviewed this report on Form N-CSR of Aspiriant Capital Appreciation Fund;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the
financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this
report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial
reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to
be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to
the filing date of this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting
that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the
registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed to the registrant's auditors
and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and
report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: | 6/5/2026 | /s/ Benjamin Schmidt |
|  |  | Benjamin Schmidt |
|  |  | President and Principal Executive Officer |

---

I, Laura Boucher, certify that:

1. I have reviewed this report on Form N-CSR of Aspiriant Capital Appreciation Fund;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the
financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this
report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial
reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to
be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to
the filing date of this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting
that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the
registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed to the registrant's auditors
and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and
report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: | 6/5/2026 | /s/ Laura Boucher |
|  |  | Laura Boucher |
|  |  | Treasurer and Principal Financial Officer |

---

## Exhibit 99.906

**Exhibit 99.906.CERT**

**Aspiriant Capital Appreciation Fund**

**Exhibit 19(b) to Form N-CSR**

CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED

PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

I, Benjamin Schmidt, Principal Executive Officer of Aspiriant Capital Appreciation Fund, certify to my knowledge that:

1. The Form N-CSR of the registrant for the period ended March 31, 2026 (the "Report") fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition
and results of operations of the registrant.

---

| | | |
|:---|:---|:---|
| Date: | 6/5/2026 | /s/ Benjamin Schmidt |
|  |  | Benjamin Schmidt |
|  |  | President and Principal Executive Officer |

---

I, Laura Boucher, Principal Financial Officer of Aspiriant Capital Appreciation Fund, certify to my knowledge that:

1. The Form N-CSR of the registrant for the period ended March 31, 2026 (the "Report") fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition
and results of operations of the registrant.

---

| | | |
|:---|:---|:---|
| Date: | 6/5/2026 | /s/ Laura Boucher |
|  |  | Laura Boucher |
|  |  | Treasurer and Principal Financial Officer |

---

Signed originals of the written statements required by Section 906 have been provided to the Aspiriant Capital Appreciation Fund, and will be retained and furnished to the Securities and Exchange Commission or its staff upon request.